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ABSTRACT OF DISSERTATION 
TIER 1 GENOMIC APPLICATIONS:  A KENTUCKY STATE NEEDS 
ASSESSMENT 
Paper 1:  An Assessment of Kentucky Cancer Registry Data for Appropriate 
Referral to Genetic Services for Hereditary Breast and Ovarian Cancer 
Syndrome and Lynch Syndrome, 2009-2012 
BACKGROUND:  It is estimated that over 1 million people in the United States 
have Hereditary Breast and Ovarian Cancer syndrome (HBOC) or Lynch 
syndrome (LS).  Evidence-based guidelines for identifying individuals with HBOC 
and LS are available, and the CDC has developed a toolkit to provide guidance 
for the implementation of programs to increase identification of patients 
appropriate for cancer genetic services. However, most individuals with HBOC 
and LS remain undiagnosed.  While some state public health departments have 
pioneered programs in public health genetics, many states, including Kentucky, 
have conducted little work in this area.  This study utilizes Kentucky Cancer 
Registry data to estimate the number of cases of breast, ovarian, fallopian tube, 
colorectal and endometrial cancers diagnosed between 2009-2012 that would 
meet guidelines for referral to genetic services in order to determine the state’s 
need for public health genetics programs that target hereditary cancer 
syndromes. 
METHODS:  Kentucky Cancer Registry data for all diagnoses of breast, ovarian, 
fallopian tube, colorectal and endometrial cancers between 2009-2012 was 
obtained.  Evidence-based guidelines from NCCN, EGAPP, and ACMG/NSGC 
were applied to the data to determine the number of cases that met criteria for 
referral to genetic services.  Descriptive statistics were performed to generate 
count data and referral groups were compared using chi-square statistics.  The 
most recent year of data (2012) was used to analyze the distribution of cases 
across Kentucky counties and Area Development Districts (ADDs). 
RESULTS:  Of the 28,109 cases of breast, ovarian, fallopian tube, colorectal, and 
endometrial cancer diagnosed in Kentucky between 2009-2012, 15,477 (55.1%) 
were determined to meet guidelines for referral including 4229 cases of breast 
cancer, 1057 cases of ovarian and fallopian tube cancers, 9815 colorectal 
cancers and 376 endometrial cancers.  Chi-square analysis indicated that cases 
in the referral group were more likely to be from individuals identified as black 
(p=0.0005), individuals with late stage caners (p<0.0001), individuals from 
Appalachian counties (p=0.0006) and individuals who are deceased (p<0.0001).  
Analysis of cases by county show that 10% (12/120) Kentucky counties and 60% 
of ADDs have genetic counseling services. 
DISCUSSION:  This study represents the first analysis of Kentucky Cancer 
Registry data to identify cancer cases appropriate for referral to genetic services 
and has identified that a significant number of cases each year would be 
appropriate for referral.  Identification of patients with HBOC and LS allow for the 
appropriate planning for cancer prevention, screening, and treatment in both 
index cases and their relatives. Population-based programs for the identification 
and referral of patients who would benefit from genetic services should be 
considered in Kentucky.  In order to accommodate additional referrals that would 
likely result, efforts should be made to expand the genetic counseling workforce 
in Kentucky.   
 
 
 
Paper 2:  Utilizing Medicaid Claims Data to Assess the Use of Genetic Testing 
for Hereditary Breast and Ovarian Cancer Syndrome in Kentucky and 
Characteristics that Influence Genetic Testing Completion 
BACKGROUND:  Hereditary Breast and Ovarian Cancer syndrome (HBOC) is a 
genetic condition that causes a significantly increased risk for breast, ovarian and 
other cancers.  Genetic testing of the BRCA1 and BRCA2 genes has been 
available commercially for nearly 20 years; however, many individuals with 
HBOC remain unaware of their increased cancer risks.  Factors that affect 
referral to and uptake of genetic counseling and testing have been previously 
reported including race, age, physician type, marital status, increased risk for 
breast cancer, and knowledge of genetics.  This study utilizes Kentucky Medicaid 
Claims data to examine how many individuals diagnosed with breast, ovarian or 
fallopian tube cancer actually received genetic testing and to determine the 
specific socio-demographic factors associated with obtaining genetic testing in 
Kentucky.   
METHODS:  A cross-section of Kentucky Medicaid Claims data for the years 
2009-2012 for individuals diagnosed with breast, ovarian or fallopian tube cancer 
was utilized in this study to determine how many individuals appropriate for 
genetic counseling and testing based on select NCCN guidelines actually 
received this testing.  Descriptive statistics were performed to generate count 
data.  T-test and chi-square tests were used to determine difference between 
individuals who had a claim for genetic testing and individuals who did not.   
Logistic regression was performed to determine variables that affected whether a 
person had genetic testing while controlling for possible confounders.   
RESULTS:  This study found 3144 patients with a Medicaid claim between 2009-
2012 who had a diagnosis of breast cancer and were age 50 or younger, male 
breast cancer, ovarian or fallopian tube cancer.  Of these individuals, 241 (7.7%) 
also had a claim for genetic testing.  Of individuals who were appropriate for 
referral, 43.61% lived within 50 miles of a full-time, on-site genetic counseling 
clinic, and distance from a genetic counseling clinic was not found to be 
significantly associated with genetic testing.  Logistic regression results showed 
that the odds of having genetic testing decreased by 13.2% for every 5 years 
increase in patient age (OR=0.868, p<0.0001).  Being diagnosed with female 
breast cancer (OR=9.137, p<0.0001), and having an appointment with a 
gynecologist (OR=1.816, p=0.0083) or oncologist (OR=3.599, p<0.0001) were all 
statistically significantly associated with an increase in the odds of receiving 
genetic testing.   
DISCUSSION:  This study was the first to use Medicaid Claims data in Kentucky 
to determine the use of genetic testing among individuals who meet evidence-
based guidelines for referral to genetic services.  This study found a low uptake 
of genetic testing in this population (7.7%), although this is likely an 
underestimate of the number of individuals who had genetic testing given that 
this was a cross-sectional data set where individuals may have had genetic 
testing outside of the study time frame.  Given the results of this study, strategies 
need to be considered by the public health workforce for increasing the number 
of individuals at-risk for hereditary cancer syndromes who are referred to and 
receive cancer genetic services.  Continued research of the utilization of genetic 
testing in Kentucky and barriers to referral and uptake of genetic testing need to 
be done to further inform program development. 
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A. INTRODUCTION 
The Centers for Disease Control and Prevention (CDC) has designated 
genetic counseling, family health history, and/or genomic testing for a number of 
genetic diseases as Tier 1 Genomic Applications. These applications are based 
on analytic validity, clinical validity, clinical utility and existing evidence-based 
guidelines indicating that the use or test is ready for population-based 
implementation 1,2.  Inherited genetic syndromes with Tier 1 Applications include 
Hereditary Breast and Ovarian Cancer (HBOC), Lynch syndrome (LS), Familial 
Hypercholesterolemia (FH), and diseases included on the Newborn Screening 
(NBS) Recommended Uniform Screening Panel (RUSP), among others 2.  The 
CDC recently published a Genomic Applications Toolkit that contains best 
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practice examples for addressing the Tier 1 Genomic Applications at the level of 
local and state health departments 3.  Phase 1 approaches focus on several 
broad activities including identifying individuals appropriate for testing, informing 
policy, conducting surveillance, and providing education 3.  These Phase 1 
approaches can be used to prepare a state for cascade screening, which is the 
main Phase 2 approach 3.  Cascade screening is the process of identifying 
individuals appropriate for genetic counseling and testing by systematically 
offering services to the relatives of index cases found to have one of the included 
genetic disorders.  To date, few states have started the process of developing 
programs to address Tier 1 Genomic Applications. 
Two of the genetic conditions with tier 1 genomic applications are HBOC 
and LS, which are the primary focus of this dissertation.  It is estimated that 
1/500 to 1/300 individuals in the general population have a BRCA1 or BRCA2 
mutation, either of which causes HBOC 4.   Approximately 5% of female breast 
cancer (9.5% of breast cancers diagnosed under age 50), 25% or more of male 
breast cancers, up to 18% of ovarian cancers, and up to 30% of fallopian tube 
cancers are due to mutations in BRCA1 and BRCA2 5–8.   
LS is caused by mutations in one of five known genes:  MLH1, MSH2, 
MSH6, PMS2, and EPCAM.   LS has a population prevalence as high as 1 in 440 
and is responsible for an estimated 2-4% of colorectal cancer diagnoses9–12.  
Individuals with LS have an increased risk for colorectal, endometrial, ovarian, 
stomach, small bowel, hepatobiliary tract, urinary tract, brain and central nervous 
system, and skin cancers over the person’s lifespan13.   
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Although individuals with HBOC and LS have a significantly increased 
lifetime risk for certain cancers, there are steps that can be taken to prevent 
cancer or diagnose it early when people know that they are at increased risk.  
Individuals with HBOC or LS can undergo preventive surgery, pursue increased 
screening for certain cancers, and/or take medications to reduce cancer risk12–15.  
Furthermore, family members of individuals with HBOC or LS may also be at 
very high risk for cancer and could benefit greatly from knowing this information 
and pursuing preventive measures.  Thus, utilizing the CDC Toolkit to implement 
genomics programs to increase the use of this primary prevention measure may 
have a significant impact on reducing cancer incidence and deaths.  Currently, 
genetic risk assessment and testing for HBOC and LS are not offered to all 
appropriate patients.  A recent study found that physicians correctly identified 
only 41% of women at high risk for HBOC and referred them for genetic 
counseling and testing 16.  In a study conducted in Louisville, Kentucky, clinic 
appointments were reviewed over a one year period, identifying over 500 women 
who were appropriate for genetic counseling for HBOC, but had not been 
previously referred. 17.   
All states in the United States have been involved with the provision of 
public health genetic services since 1985, when Mississippi became the last 
state to implement a state newborn screening program 18.  More recently, some 
states have been working on state needs assessments, planning, and program 
implementation to further incorporate genomics into state public health 
programs19.  To date, Kentucky has not implemented any official programs in 
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local or state health departments to address the CDC Tier 1 Genomic 
Applications.  However, Kentucky does have a number of assets that can be 
utilized to prepare for and implement Phase 1 programs.  One example is the 
robust Kentucky Cancer Registry that collects data on every case of cancer 
diagnosed in the state.  Guidelines from the National Comprehensive Cancer 
Network (NCCN), Evaluation of Genomic Applications in Practice and Prevention 
(EGAPP) workgroup, the American College of Medical Genetics (ACMG), and 
the National Society of Genetic Counselors (NSGC) for identifying individuals at 
risk for hereditary cancer syndromes could be used to screen the Kentucky 
Cancer Registry data already being collected12–14,20.  This could lead to bi-
directional cancer registry reporting, which involves a two-way exchange of 
information between the state cancer registry and reporting institutions in the 
state including hospitals and physician offices, being implemented through the 
Kentucky Cancer Registry office and the Kentucky Department of Public Health. 
In a bidirectional cancer registry reporting system, an algorithm developed from 
national guidelines is applied to data already being collected by the state cancer 
registry to identify individuals who are potentially at increased risk for HBOC and 
LS.  Information about patients who are potential candidates for genetic 
counseling and testing, as well as educational information, is reported back to 
cancer registrars, physicians, hospital administrators, and/or patients to assist 
providers in referring patients and their relatives to appropriate services for 
genetic risk assessment and testing21. 
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There are a number of barriers to implementing Phase 1 programs from 
the CDC Genomics Application Toolkit in Kentucky.  First, funding for public 
health genetics and genomics projects is limited, and implementation would likely 
require significant staff hours and materials costs.  At this time, Kentucky has few 
individuals in the Kentucky Department of Public Health with experience in 
genetics, and furthermore, the state does not have an adequate supply of 
genetics professionals to provide appropriate services to new individuals who are 
identified for genetic risk assessment.  In addition, many public health providers, 
healthcare providers, and lay people know very little about inherited genetic 
conditions and the importance of genetic counseling and testing.  Educational 
materials and programs would need to be developed in order to prepare the 
public health and medical workforce for a public health program that addresses 
screening for HBOC, LS, or other disorders with tier 1 genomic applications.  
Finally, there have been few previous studies in Kentucky that have attempted to 
quantify the number of individuals at risk for HBOC, LS and the other conditions 
included in the Tier 1 Genomic Applications.   
 
B. PROBLEM STATEMENT 
 Genetic counseling and/or testing for HBOC and LS has been available for 
approximately twenty years.  The provision of these services has traditionally 
been based on a medical provider-patient model where patients are referred for 
counseling and testing by a physician or other health care provider.  In order for 
this to occur, personal and family history should be collected for each patient and 
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addressed by the health care provider.  Individuals referred for services are 
typically seen on an individual basis by a genetic counselor and/or other provider.   
 Given the growing body of knowledge regarding HBOC and LS, the type of 
people who are appropriate for counseling and testing is growing, and the 
importance of family history in recognizing these syndromes, while still important 
in many situations, has been shifting to broader population-based models for 
identification of at-risk individuals 7,8,22,23.  This shift in thinking about patient 
identification for genetic services is likely to assist in the identification of 
individuals who are appropriate candidates for genetic counseling and testing by 
increasing provider and public awareness about the disease.  However, a shift to 
a public health model will require a significant amount of preparation and 
planning as most public health departments and programs have had little 
experience with genetics and genomics outside of state newborn screening 
programs.   
 The recognition that genetics and genomics is becoming an important aspect 
of public health is reflected in the addition of genomic goals to the Healthy 
People 2020 goals for first time.  Healthy People 2020 goals are evidence-based 
goals for health improvement in the United States over a ten year period.  The 
Healthy People 2020 goal in genomics is to, “Improve health and prevent harm 
through valid and useful genomic tools in clinical and public health practices” 24.  
A specific objective of the goal relating to HBOC is to, “Increase the proportion of 
women with a family history of breast and/or ovarian cancer who receive genetic 
counseling,” from 34.6% to 38.1% (10% increase) 24.  Select state and national 
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public health organizations are now taking steps toward implementing programs 
in an effort to meet these goals. 
 In order to implement public health genomic programs in the near future, 
states must assess their current strengths, weaknesses, opportunities and goals 
regarding public health genetics.  Data will be required to identify the needs of 
the state’s population, disparities in access to genetic services, and the capacity 
of the state to assure the provision of services to residents.  Currently, Kentucky 
lacks public health genetics capacity outside of the state newborn screening 
program and has little available data regarding public health genetics activities.  
Furthermore, the state is currently serviced by only 19 genetic counselors, or 1 
genetic counselor per 232,000 individuals 25,26.  While other states have pursued 
data collection studies and implemented programs to increase education, 
surveillance of, and access to genetic counseling and testing among their 
residents 27–30, Kentucky has done little to collect the data needed to assess the 
needs and capacity of the state to identify individuals appropriate for genetic 
services encompassed by the CDC Tier 1 Genomic Applications and to assure 
access to those services.   
 
C. PURPOSE OF DISSERTATION 
 To date, the presence of genetics and genomics in public health has been 
exemplified by state newborn screening programs, which screen nearly all infants 
born in the U.S. for severe inherited diseases including metabolic, endocrine, 
hemoglobin and other disorders 31. However, evidence-based guidelines for 
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identifying and diagnosing other genetic diseases, including HBOC and LS, 
across the lifespan have recently been developed where public health programs 
could play an important role in implementation12–14,20.  The CDC has recognized 
that these genetic diseases have Tier 1 Genomic Applications, and is calling on 
state and local health departments to take action in the areas of policy, 
education, surveillance, and clinical intervention as the first steps to developing 
public health programs regarding these diseases 1.   
 This dissertation will encompass the first steps in a Kentucky state needs 
assessment for implementing Tier 1 Genomic Applications.  The dissertation will 
provide information on two of the three Public Health Core Functions—
assessment and assurance—with a focus on HBOC and LS.  The results of the 
dissertation will provide information on Kentucky’s strengths, opportunities and 
barriers to implementing public health based programs to promote genetic 
counseling and testing.  This will allow for future informed program planning to 
address HBOC, LS, and other Tier 1 Genomic Applications to best meet the 
unique needs of Kentuckians.  Specifically, the first study will address public 
health surveillance by utilizing Kentucky Cancer Registry data to assess 
individuals diagnosed with breast, ovarian, fallopian tube, colorectal and 
endometrial cancers in Kentucky to determine how many of these individuals 
would be appropriate for referral to cancer risk assessment services based on 
select NCCN, USPSTF (United States Preventive Services Task Force), EGAPP, 
and ACMG/NSGC guidelines 12–14,32.  This analysis will provide the first estimate 
of how many individuals diagnosed with these cancers in Kentucky may benefit 
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from HBOC and LS genetic counseling and testing. It will also examine the 
potential contribution of HBOC and LS to late stage cancers and the distribution 
of at-risk individuals across the state. Study two will utilize Medicaid data to 
determine what characteristics might influence an individual’s access to genetic 
testing for HBOC.  The study will detect potential barriers to and disparities in 
care that may be encountered as larger public health programs that aim to 
identify and refer individuals to genetic services are developed.     
 Aggregated together, the results of the two studies encompassed in this 
dissertation will provide some of the groundwork needed for Kentucky to begin to 
address public health genetics and genomics in the state.  More work will need to 
be done, but this dissertation should provide the preliminary information needed 
to begin to build the funding and infrastructure for further assessment and 
program implementation.  Addressing inherited causes of common diseases in 
Kentucky could contribute significantly to reducing diagnoses of and/or deaths 
from these diseases. 
D. RESEARCH QUESTIONS 
This dissertation focuses on the following research questions as the basis for 
conducting the first steps of a Kentucky state needs assessment for the 
implementation of Tier 1 Genomic Applications: 
1. How many patients diagnosed with breast, ovarian, fallopian tube, 
colorectal, and endometrial cancer in Kentucky between January 2009 
and December 2012 meet certain NCCN, EGAPP, or ACMG/NSGC 
guidelines for genetic risk assessment referral? (Assessment) 
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2. What is the contribution of breast, ovarian, fallopian tube, colorectal and 
endometrial cancers that are likely due to HBOC or LS to the incidence of 
late stage cancers and cancer mortality in Kentucky?  (Assessment) 
3. What is the availability of genetic counseling services to individuals at risk 
for HBOC and LS?  (Assurance) 
4. What characteristics influence whether an individual diagnosed with 
breast, ovarian, or fallopian tube cancer in Kentucky who is eligible for 
genetic testing receives genetic testing of the BRCA1 and BRCA2 genes? 
(Assessment) 
E. RESEARCH HYPOTHESES 
Study 1:  An Assessment of Kentucky Cancer Registry Data for Appropriate 
Referral to Genetic Services for Hereditary Breast and Ovarian Cancer 
syndrome and Lynch syndrome, 2009-2012 
 Hypothesis:  There are not a significant number of individuals diagnosed 
with breast, ovarian, fallopian tube, colorectal, and endometrial cancers who 
are appropriate for genetic counseling and testing services in Kentucky, and 
currently the available genetic services are sufficient to meet this need.   
Study 2:  Utilizing Medicaid Claims Data to Assess the Use of Genetic Testing 
for Hereditary Breast and Ovarian Cancer Syndrome in Kentucky and 
Characteristics that Influence Genetic Testing Completion 
 Hypothesis:  There are no significant differences between individuals who 
are appropriate for genetic testing for HBOC and receive vs. do not receive 
testing. 
11 
 
F. SCOPE AND IMPORTANCE 
It has been recognized by the CDC that involvement of state and local health 
departments in public health genomics will be vital for the appropriate 
identification and care of individuals at risk for genetic diseases over the lifespan 
1,27.  The information generated from this dissertation will yield the first 
surveillance data in Kentucky regarding the need for public health genomics 
programs for HBOC and LS.  The results of these studies will also contribute to 
the growing body of state specific literature on public health genomics issues.  
Although needs assessment for public health genomics has been done in other 
states, specific information about the population of Kentucky will lay the 
groundwork for further research and program implementation locally.  This is 
fundamentally important to the health of Kentucky residents, especially given that 
the state has highest cancer incidence rate among the fifty states and District of 
Columbia 33.  Furthermore, in March 2014, Kentucky Governor Steve Beshear 
announced the KY Health Now goals, which include reducing Kentucky cancer 
deaths by 10% by 2019 34.  A significant proportion of certain cancers are caused 
by genetic conditions with Tier 1 genomic applications, with HBOC being 
responsible for approximately 5% of female breast cancer (9.5% of breast 
cancers diagnosed under age 50) and 18% of ovarian cancers5,6,8 and LS being 
responsible for 2-4% of colon cancers 12.  Identifying individuals at risk for these 
diseases can allow for prevention of disease, appropriate treatment, or early 
diagnosis through increased screening.  Focusing on primary prevention in the 
individuals most at risk for these common diseases would be expected to 
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significantly contribute towards meeting the KY Health Now goals, especially 
when combined with other efforts in the state to decrease environmental and 
lifestyle risks. 
G. LIMITATIONS AND DELIMITATIONS 
Each of the studies included in this dissertation have unique limitations, which 
are discussed in subsequent chapters.  More broadly, the studies are secondary 
data analyses, which are associated with specific limitations including not having 
access to some important data points that could make the study more robust and 
the researchers not having direct control over data quality.  However, the 
secondary data is being obtained from two high quality data sets—the Kentucky 
Cancer Registry and Kentucky Medicaid Claims—which help to minimize these 
concerns.   
This dissertation includes two studies that represent the beginning of a needs 
assessment in Kentucky for public health genomics, but is not comprised of all 
the necessary components for a complete state needs assessment.  
Furthermore, the dissertation focuses on HBOC and LS, and additional research 
will need to be done to address other diseases with Tier 1 Genomic Applications.   
An additional delimitation of this dissertation is lack of generalizability.  The 
data involved in each study is specific to the state of Kentucky, so results may 
not be able to be generalized to needs in other states.  This is an appropriate 
approach to this project as public health genetic and genomic programs have 
traditionally been developed and implemented on a state-by-state basis, allowing 
states to tailor programs to coincide with state health initiatives and to reflect the 
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needs of the state’s population.  Although the results of this study cannot be 
generalized outside of Kentucky, the methods used in each of the studies can 
certainly be applied in other states as part of a needs assessment for public 
health genomic programs. 
H. ADVANCE ORGANIZER FOR DISSERTATION 
The chapters of this dissertation are organized to reflect the two papers 
generated by the research project, each of which has a self-contained literature 
review, methods, results, and discussion section.  The present chapter (Chapter 
I) provides an introduction to the body of work encompassed in subsequent 
chapters.  Chapter II is the paper generated from Study 1, An Assessment of 
Kentucky Cancer Diagnoses for Appropriate Referral to Genetic Services for 
Hereditary Breast and Ovarian Cancer, 2009-2012.  Chapter III contains the 
paper from Study 2, Characteristics that Influence Genetic Testing Completion 
for Hereditary Breast and Ovarian Cancer in Kentucky.  Chapter IV provides a 
summary of the conclusions from the body of research as well as 
recommendations for future research and public health program implementation. 
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CHAPTER 2 
PAPER 1:  AN ASSESSMENT OF KENTUCKY CANCER 
REGISTRY DATA FOR APPROPRIATE REFERRAL TO GENETIC 
SERVICES FOR HEREDITARY BREAST AND OVARIAN CANCER 
SYNDROME AND LYNCH SYNDROME, 2009-2012 
 
A. INTRODUCTION 
B. MATERIALS AND METHODS 
C. RESULTS 
D. DISCUSSION 
 
A.  INTRODUCTION 
Hereditary Breast and Ovarian Cancer syndrome (HBOC) and Lynch 
syndrome (LS) are two hereditary cancer syndromes that cause an increased 
lifetime risk for specific cancers in affected individuals.  It is estimated that over 
one million people in the United States have HBOC or LS1.  HBOC caused by 
mutations in the BRCA1 and BRCA2 genes is associated with up to a 71% 
lifetime risk for breast cancer and up to a 46% lifetime risk for ovarian, fallopian 
tube and primary peritoneal cancer2.  HBOC is responsible for approximately 5% 
of female breast cancer (9.5% of breast cancers diagnosed under age 50), 25% 
or more of male breast cancers, up to 18% of ovarian cancers, and up to 30% of 
fallopian tube cancers3–6. LS causes a 45% or greater lifetime risk for colorectal 
cancer as well as increased risks for other cancers including endometrial, 
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ovarian, stomach, hepatobiliary tract, urinary tract, small bowel, and brain/central 
nervous system cancers7,8.  Approximately 2-4% of colorectal cancers are due to 
LS7.   
Individuals who have already been diagnosed with cancer that is found to be 
due to HBOC or LS are at a significantly increased risk for developing a second 
cancer in the future.  Their relatives are at risk for also having the inherited 
cancer syndrome, with first degree relatives (parents, siblings, children) having a 
50% chance to inherit the disease-causing, germ-line mutation, and second 
degree relatives (grandparents, aunts, uncles, nieces, nephews, grandchildren, 
etc.) having a 25% chance to inherit the mutation.  Other, more distant family 
members are also at risk for carrying the same genetic mutation.  Therefore, the 
identification of index cases in families with HBOC or LS has the potential to not 
only help the individual best manage his or her cancer risk in the future, but also 
to help additional family members prevent cancer or take steps to diagnose 
cancer at the earliest possible stage through increased screening.  The process 
of systematically identifying at-risk relatives of an index case has been termed 
cascade screening, and is recommended by the CDC as the method for Phase II 
implementation of the Tier 1 Genomic Applications.9 
Identifying individuals and their family members with a significantly increased 
risk for cancer is a way of utilizing a primary prevention measure to reduce 
cancer incidence and deaths.  While individuals with HBOC and LS have 
significantly increased lifetime cancer risks compared to the general population, 
there are preventive measures including surgical interventions, increased 
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screening, and medications that can be taken to reduce their cancer risks or 
diagnose a cancer at the earliest possible stage.   
Several organizations have published national guidelines for the identification 
of individuals at risk for HBOC and LS.  In 2013 the U.S. Preventive Services 
Task Force (USPSTF) released guidelines for identifying unaffected women with 
a family history of breast or ovarian cancer who are appropriate for genetic 
counseling and testing2.  In 2009, the Evaluation of Genomic Applications in the 
Practice and Prevention (EGAPP) workgroup published guidelines on identifying 
individuals newly diagnosed with colorectal cancer who have Lynch syndrome7.  
The American College of Medical Genetics (ACMG) and the National Society of 
Genetic Counselors (NSGC) recently published joint guidelines for referral to 
genetic counseling for multiple hereditary cancer syndromes, including HBOC 
and LS10. The National Comprehensive Cancer Network (NCCN) releases 
regularly updated guidelines for the identification of individuals with and without 
cancer who are at risk for HBOC or LS8,11.  Despite these available guidelines, 
most individuals with HBOC and LS remain undiagnosed.   
HBOC and LS have been designated by the CDC as conditions with Tier 1 
Genomic Applications, which are family history and genetic testing applications 
with significant evidence, validity and utility to support implementation into public 
health practice 12.  The CDC has released a toolkit for local and state health 
departments to help these entities implement programs for the education, 
identification, and screening of individuals at increased risk for HBOC, LS, and 
other conditions 9.  The toolkit outlines two phases of implementation, with Phase 
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I implementation including bi-directional cancer registry reporting, providing 
guidance for evidence-based policy making, developing data collection tools and 
tracking data on the implementation of Tier 1 Genomic Applications, and 
providing education and outreach to providers and the public.9  Phase II 
implementation focuses on cascade screening programs9.   
Existing data sources represent an important resource that can be utilized to 
advance the implementation of Tier 1 Genomic Applications. One existing data 
source, state cancer registries, contains important information that has the 
potential to be used to identify individuals who are at risk for HBOC and LS.  In 
the U.S., each state maintains a central cancer registry that collects detailed 
information on each case of cancer that is diagnosed in the state for public health 
purposes. Typically, a standard set of information about each diagnosis of cancer 
is reported from cancer registries at healthcare institutions to the state cancer 
registry.  This results in a comprehensive, population-based dataset that can be 
used to address state and national surveillance and research questions 
regarding cancer.  Bidirectional cancer registry reporting is a process where an 
algorithm developed from national guidelines is applied to the data already being 
collected by the state cancer registry to identify specific sets of individuals who 
are at increased risk for HBOC and LS13. 
Several states have already utilized cancer registry data in implementing 
Phase I recommendations, specifically in the creation of bidirectional cancer 
registry programs9,14,15. Michigan, Connecticut, Colorado, and Oregon have used 
cancer registry data in the implementation of bidirectional cancer registry 
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reporting programs to identify individuals diagnosed with cancer who were at risk 
for having HBOC and/or LS13.  This information was then reported back to 
institutions, physicians and/or patients.  Although bidirectional cancer registry 
reporting programs will vary by state depending on resources, state law, and 
infrastructure, all programs will begin with an analysis of cancer registry data in 
order to identify those patients who are potentially at risk for HBOC and/or LS.   
There are some states that have pioneered programs for addressing the CDC 
Tier 1 Genomic Applications, established public health genetics and genomics 
programs, and secured funding for public health genetics programs15.  In 
contrast, most states, including Kentucky, have conducted little work in this area.  
A data analysis to determine the impact of a bidirectional cancer registry 
reporting program has not been conducted in Kentucky.  The first step to 
program implementation is a demonstration of need, and this study aims to 
estimate the number of cases of newly diagnosed breast, ovarian, fallopian tube, 
colorectal and endometrial cancers that would meet certain national guidelines 
for genetic risk assessment referral for HBOC and LS.  This study will provide 
information regarding the current need for genetic counseling and testing for 
HBOC and LS in Kentucky and provide preliminary information for use in the 
planning and implementation of public health programs to increase awareness 
and utilization of cancer genetic services.   
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B. MATERIALS AND METHODS 
Data Source 
The data set analyzed for this study was obtained from the Kentucky Cancer 
Registry located in Lexington, KY.   The Kentucky Cancer Registry is the state 
cancer registry, which collects data on each case of cancer diagnosed in the 
state of Kentucky.  Beginning in 1994, Kentucky state law KRS 214.556 requires 
all Kentucky hospitals, their associated outpatient facilities, and other health care 
facilities that diagnose or treat cancer patients to report every case of cancer 
diagnosed to the registry16.  Each year, the registry receives data on the over 
28,000 primary cancer cases diagnosed in Kentucky residents16.  Quality control 
is addressed through a number of measures including the re-abstraction of a 
subset of cases by cancer registrars employed by the registry 16.  This process 
increases the validity and reliability of the data to represent an accurate picture of 
cancer diagnoses in Kentucky.  However, threats to validity and reliability may 
include incomplete or inaccurate information recorded in patient medical records, 
cases not reported to or identified by the registry, and/or mistakes in abstracting 
that cannot be detected through the extensive edit checks implemented in 
software applications used to capture registry data.  Complete, population-based 
data is currently available in the Kentucky Cancer Registry through 2012. 
The data subset used in this study was obtained from the Kentucky Cancer 
Registry after completing the appropriate application for release of data and 
obtaining IRB approval from the University of Kentucky IRB.  Breast, ovarian, and 
colorectal cancer cases were selected based on cancer site and year of 
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diagnosis.  Fallopian tube and endometrial cancers were selected based on 
cancer site, histology and year of diagnosis.  The final data subset contained 
case based information.  While individual patients may have had multiple cancers 
diagnosed during the study period, this could not be determined from the data 
set, and each diagnosis was considered separately.  The cross sectional data 
subset included 28,109 observations, which represent all cases of breast 
(n=14,812), ovarian (n=1036), fallopian tube (n=121), colorectal (n=9815) and 
endometrial (n=2325) cancers diagnosed in Kentucky from 2009-2012.       
Data Analysis 
The data set was reviewed and then loaded into SAS version 9.3 and R 
version 3.1.3, which were used to conduct the data analysis.  The data set 
contains no missing data values.  Descriptive statistics were run to generate 
count data to measure the number of individuals newly diagnosed with breast, 
ovarian, fallopian tube, colorectal and endometrial cancer each year who would 
be appropriate for referral to genetic services.  Chi-square analyses were used to 
determine whether there were statistically significant differences between cases 
that did and did not meet the referral guidelines examined in this study. 
The following national guidelines were used to identify which cases were 
appropriate for genetic counseling and testing: 
Hereditary Breast and Ovarian Cancer syndrome (NCCN Criteria)11 
 Women diagnosed with breast cancer ≤ 50y 
 Women diagnosed with triple negative breast cancer 
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 Women diagnosed with epithelial ovarian or fallopian tube cancer at any 
age 
 Men diagnosed with breast cancer at any age 
Lynch syndrome 
 Any individual diagnosed with colorectal cancer (EGAPP)7 
 Endometrial cancer diagnosed at age < 50y10 
 
The data set was then subdivided into four sub-sets based on these criteria:  
1) Breast cancer cases that were diagnosed at age 50 or younger, breast cancer 
cases diagnosed in a male, or breast cancer cases that were triple negative (ER, 
PR and HER2 negative) at any age, 2) Ovarian cancer cases excluding 
histologies that are known not to be associated with hereditary breast and 
ovarian cancer syndrome (mucinous tumors, germ cell tumors, neuroendocrine 
tumors and benign tumors 6,17) or fallopian tube cancer cases, 3) Colorectal 
cancer cases, and 4) Endometrial cancer cases under age 50.  Additional 
descriptive statistics were generated for each sub-set of data.   
The numbers of cancer diagnoses meeting the above stated criteria for 
appropriate referral to genetic counseling and/or testing in 2012 were calculated 
for each county in Kentucky as well as the 15 Kentucky Area Development 
Districts (ADDs).  The locations of cancer genetic counseling clinics and outreach 
services were obtained through key informant interviews with genetic counselors 
in the state of Kentucky.  This information was used to determine the number of 
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genetic counselors in the state as well as which counties and ADDs had access 
to genetic counseling services.   
 
C. RESULTS 
A total of 28,109 breast, ovarian, fallopian tube, colorectal and endometrial 
cancer cases diagnosed between 2009-2012 were included in the original data 
set.  Of these cancers, 4847 (17.2%) were diagnosed at or before age 50.  In this 
data set, 92.7% of cancer cases were diagnosed in individuals whose race was 
identified as white, 6.8% in individuals identified as black, and 0.53% in 
individuals of other races. Cancer stage at diagnosis was also evaluated using 
the variable best stage group, which is derived from the collaborative stage and 
incorporates both pathological and clinical stages18.  While the majority of 
cancers (70.1%) were diagnosed at an early stage (Stage 0, 1 or 2) as defined 
by the best stage group (a calculated registry value from the pathological and 
clinical TNM stage groups), this varied by cancer type with early stage diagnoses 
occurring more often in breast (83.18% of cancers) and endometrial (75.57%) 
cancers and less often in colorectal (53.57%) and ovarian/fallopian tube 
(31.72%) cancers.  Cases diagnosed in Appalachian counties comprised 27.98% 
of all cancer diagnoses in the data set.  Descriptive statistics for the full data set 
are summarized in Table 1.   
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Table 1:  Full sample demographics 
  
Breast 
(n=14,812) 
Ovarian/FT 
(n=1157) 
Colorectal 
(n=9,815) 
Endometrial 
(n=2,325) 
Total               
(n=28,109) 
Age at dx  N % N % N % N % N % 
     < 35 years 225 1.52% 34 2.94% 98 1.00% 46 1.98% 403 1.43% 
     35-50 years 2919 19.71% 180 15.56% 1015 10.34% 330 14.19% 4444 15.81% 
     51-65 years 5806 39.20% 421 36.39% 3269 33.31% 1158 49.81% 10654 37.90% 
     > 65 years 5862 39.58% 522 45.12% 5433 55.35% 791 34.02% 12608 44.85% 
Sex                     
     Male 84 0.57% 0 0.00% 5107 52.03% 0 0.00% 5191 18.47% 
     Female 14728 99.43% 1157 100.00% 4708 47.97% 2325 100.00% 22918 81.53% 
Race                     
     White 13596 91.79% 1098 94.90% 9033 92.03% 2180 93.76% 25907 92.17% 
     Black 1075 7.26% 52 4.49% 669 6.82% 122 5.25% 1918 6.82% 
     Other 82 0.55% 6 0.52% 49 0.50% 11 0.47% 148 0.53% 
     Unknown 59 0.40% 1 0.09% 64 0.65% 12 0.52% 136 0.48% 
Year of 
Diagnosis                     
     2009 3637 24.55% 292 25.24% 2515 25.62% 522 22.45% 6966 24.78% 
     2010 3631 24.51% 282 24.37% 2416 24.62% 543 23.35% 6872 24.45% 
     2011 3698 24.97% 280 24.20% 2414 24.60% 588 25.29% 6980 24.83% 
     2012 3846 25.97% 303 26.19% 2470 25.17% 672 28.90% 7291 25.94% 
Cancer Stage                     
     Stage ≤ 2 12320 83.18% 367 31.72% 5272 53.71% 1757 75.57% 19716 70.14% 
     Stage 3 or 4 2077 14.02% 680 58.77% 3757 38.28% 339 14.58% 6853 24.38% 
Other/Unknow
n 415 2.80% 110 9.51% 786 8.01% 229 9.85% 1540 5.48% 
Appalachia 
County                     
     
Appalachian 3757 25.36% 337 29.13% 3011 30.68% 759 32.65% 7864 27.98% 
     Non-
Appalachian 11055 74.64% 820 70.87% 6804 69.32% 1566 67.35% 20245 72.02% 
 
When the previously described evidence-based guidelines for referral to 
genetic services are applied to this data set, 15,477 (55.1%) of the 28,109 cases 
were determined to be appropriate for referral.  Of the 14,812 cases of breast 
cancer diagnosed between 2009 and 2012, 4229 (28.55%) were included in the 
final data set because they were found to be diagnosed at or younger than age 
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50, to have triple negative breast cancer, or to be male.  Of the 1157 women who 
were diagnosed with ovarian and fallopian tube cancer in 2009-2012, 1057 
(91.36%) were included in the data sent, including 936 ovarian cancers with 
histologies consistent with a possible hereditary ovarian cancer and all fallopian 
tube cancers (121 cases).  In the original data set, 2325 women were diagnosed 
with endometrial cancer, and 376 (16.17%) were diagnosed at or under age 50, 
thus meeting criteria for inclusion in the final data set.  All cases of colorectal 
cancer are appropriate for referral based on the EGAPP guidelines and included 
in the final data set.  Cases identified as being appropriate for referral to genetic 
services are summarized in Table 2.  
Table 2:  Cancer Cases Appropriate for Referral to Genetic Services 
  Breast Ovarian/FT Colorectal Endometrial 
2009      
     All Cases 3637 292 2515 522 
     Appropriate Referrals 1054 256 2515 94 
     Percent 28.98% 87.67% 100.00% 18.01% 
2010   
     All Cases 3631 282 2416 543 
     Appropriate Referrals 1008 259 2416 79 
     Percent 27.76% 91.84% 100.00% 14.55% 
2011   
     All Cases 3698 280 2414 588 
     Appropriate Referrals 1065 256 2414 95 
     Percent 28.80% 91.43% 100.00% 16.16% 
2012   
     All Cases 3846 303 2470 672 
     Appropriate Referrals 1102 286 2470 108 
     Percent 28.65% 94.39% 100.00% 16.07% 
Total   
     All Cases 14812 1157 9815 2325 
     Appropriate Referrals 4229 1057 9815 376 
     Percent 28.55% 91.36% 100.00% 16.17% 
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Cases that were identified as appropriate for referral to genetic services were 
further analyzed to determine the race, sex (where applicable), stage (best stage 
group), year of diagnosis, vital status and Appalachian county designation of 
identified cases. The demographics of the cases meeting criteria for referral for 
each cancer type are summarized in Table 3.  These demographics represent in 
part the referral criteria used in this study.  For example, 74.34% of breast cancer 
cases included in the referral data set where diagnosed at or under age 50, 
which is mainly due to one of the criteria for referral being age of diagnosis with 
breast cancer at or under age 50.  Furthermore, 62.06% of ovarian and fallopian 
tube cancers were diagnosed at stages 3 or 4, which is likely representative of 
ovarian and fallopian tube cancers in general being fast-growing, aggressive 
cancers that are often diagnosed at later stages.  Alternately, the cases for the 
three other cancer types had less than half of the cases diagnosed at stages 3 or 
4: breast cancer (16.34% stage 3 or 4), colorectal cancer (38.28%), and 
endometrial cancer (9.57%). 
When compared to the entire study sample, a higher percentage of cases that 
were identified as appropriate for referral were diagnosed at or under the age of 
50 (31.08% vs. 17.24% in the entire study sample) given that young age is a 
criteria for referral for both breast and endometrial cancers.  The majority of the 
cases included in this analysis were from individuals who identified as being 
white, both in the entire data set (92.17%) and in those appropriate for referral 
(91.52%). 
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Table 3: Characteristics of Cancer Cases Appropriate for Genetic Referral by 
Cancer Type 
  
Breast    
(n=4229) 
Ovarian/FT 
(n=1057) 
Colorectal 
(n=9815) 
Endometrial 
(n=376) 
Total     
(n=15477) 
Age at dx N % N % N % N % N % 
     < 35 years 225 5.32% 21 1.99% 98 1.00% 46 12.23% 390 2.52% 
     35-50 years 2919 69.02% 156 14.76% 1015 10.34% 330 87.77% 4420 28.56% 
     51-65 years 619 14.64% 385 36.42% 3269 33.31% n/a n/a 4273 27.61% 
     > 65 years 466 11.02% 495 46.83% 5433 55.35% n/a n/a 6394 41.31% 
Sex   
     Male 84 1.99% 0 0.00% 5107 52.03% 0 0.00% 5191 33.54% 
     Female 4145 98.01% 1057 100.00% 4708 47.97% 376 100.00% 10286 66.46% 
Race   
     White 3764 89.00% 1010 95.55% 9033 92.03% 358 95.21% 14165 91.52% 
     Black 403 9.53% 40 3.78% 669 6.82% 15 3.99% 1127 7.28% 
     Other 33 0.78% 6 0.57% 49 0.50% 1 0.27% 89 0.58% 
     Unknown 29 0.69% 1 0.09% 64 0.65% 2 0.53% 96 0.62% 
Cancer Stage   
     Stage ≤ 2 3460 81.82% 299 28.29% 5272 53.71% 306 81.38% 9337 60.33% 
     Stage 3 or 4 691 16.34% 656 62.06% 3757 38.28% 36 9.57% 5140 33.21% 
     Other/Unknown 78 1.84% 102 9.65% 786 8.01% 34 9.04% 1000 6.46% 
Appalachia County   
     Appalachian 1020 24.12% 307 29.04% 3011 30.68% 121 32.18% 4459 28.81% 
     Non-Appalachian 3209 75.88% 750 70.96% 6804 69.32% 255 67.82% 11018 71.19% 
Vital Status   
     Alive 3752 88.72% 551 52.13% 6066 61.80% 354 94.15% 10723 69.28% 
     Deceased 477 11.28% 506 47.87% 3749 38.20% 22 5.85% 4754 30.72% 
 
When comparing the cases that met criteria for referral to those cases that 
did not meet criteria, cases identified as being appropriate for referral had a 
higher proportion of individuals who were identified as black than in those cases 
that did not meet criteria for referral (7.37% in the referred group vs. 6.31% in the 
non-referred group, χ2=12.025, p=0.0005).  Cases that were identified as 
appropriate for referral were more likely to be stage 3 or 4 cancers (n=5140, 
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33.21%) than all cancers analyzed in the study (n=6853, 24.38%).  Cases 
appropriate for referral to genetic services were statistically significantly more 
likely to be stage 3 or 4 cancers than cases that were determined to not be 
appropriate for referral (35.50% in the referred group vs. 14.17% in the non-
referred group, χ2=1567.35, p<0.0001).  Individuals represented by the cases 
included in the referral data set were slightly more likely to be from Appalachian 
counties than in the data set as a whole (28.81% of referrals vs. 27.98% of all 
cases) and were statistically significantly more likely to be from Appalachian 
counties than those cases not identified as appropriate for referral (28.81% in the 
referred group vs. 26.96% in the non-referred group, χ2=11.88, p=0.0006).  
Individuals represented by the cases in the referral data set were less likely to be 
living (69.28%) than those determined to be not appropriate for referral (84.75%) 
(p<0.0001), which could be in part due to the fact that cases in the referral data 
set were more likely to be later stage cancers (stage 3 or 4).  These results are 
summarized in Table 4. 
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Table 4:  Comparison of Cases Appropriate for Referral to Cases Not 
Appropriate for Referral 
    Referral 
  Total No Yes 
  n=28,109 n=12,632 n=15,477 
Age at dx 
     < 35 years 403 (1.43%) 13 (0.10%) 390(2.52%) 
     35-50 years 4444(15.81%) 24 (0.19%) 4420 (28.56%) 
     51-65 years 10654(37.90%) 6381 (50.51%) 4273 (27.61%) 
     > 65 years 12608 (44.85%) 6214 (49.19%) 6394 (41.31%) 
Sex 
     Male 5191 (18.47%) 0 (0.0%) 5191 (33.54%) 
     Female 22918(81.53%) 12632 (100.0%) 10286 (66.46%) 
Race* 
     White 25907 (92.17%) 11742 (92.95%) 14165 (91.52%) 
     Black 1918 (6.82%) 791 (6.26%) 1127 (7.28%) 
     Other 148 (0.53%) 59 (0.47%) 89 (0.58%) 
     Unknown 136 (0.48%) 40 (0.32%) 96 (0.62%) 
Cancer Stage* 
     Stage ≤ 2 19716 (70.14%) 10379 (82.16%) 9337 (60.33%) 
     Stage 3 or 4 6853 (24.38%) 1713 (13.56%) 5140 (33.21%) 
     
Other\Unknown 1540 (5.48%) 540 (4.27%) 1000 (6.46%) 
Appalachia County* 
     Appalachian 7864 (27.98%) 3405 (26.96%) 4459 (28.81%) 
     Non-
Appalachian 20245 (72.02%) 9227 (73.04%) 11018 (71.19%) 
Vital Status* 
     Alive 21429 (76.24%) 10706 (84.75%) 10723 (69.28%) 
     Deceased 6680 (23.76%) 1926 (15.25%) 4754 (30.72%) 
 
In order to better characterize the annual need for cancer genetic counseling 
services for individuals with newly diagnosed cases of breast, ovarian, fallopian 
tube, colorectal and endometrial cancers across the state of Kentucky, the most 
recent year of data (2012) was used to look at distribution of cases appropriate 
for genetic referral among Kentucky counties (n=3966).  Of the 120 Kentucky 
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counties, all counties had at least 1 individual diagnosed with one of the cancers 
examined in this study who met criteria for referral to genetic counseling.  The 
five counties with the highest number of cases identified as appropriate for 
referral in 2012 were 1) Jefferson County (n=729, 18.38% of appropriate cases 
identified in the state), 2) Fayette County (n=255, 6.43%), 3) Kenton County 
(n=108, 2.72%), 4) Hardin County (n=106, 2.67%) and 5) Boone County (n=100, 
2.52%), which is expected as these five counties are included in the six highest 
populated counties in the state.  Of these 5 counties, 3 (Jefferson, Fayette, and 
Kenton) have full time genetic counseling services available in the county, Boone 
county has services available in a bordering county, and Hardin County has 
services available through outreach programs.  Overall, residents in 12/120 
counties (10%) have access to genetic counseling services in their county.  A 
summary of cases by county is included in Figure 1.  
Appropriate cases for referral in 2012 were also examined by area 
development district (ADD).  The state of Kentucky is made up of 15 ADD’s, 
which are planning and developing districts made up of multiple counties19.  The 
counties in each ADD work together to attain economic growth, improve the 
quality of life, and provide services to their residents.  The Kentuckiana Regional 
Planning and Development Agency (KIPDA) has the highest number of cancer 
cases identified as appropriate for referral to genetic counseling services (n=933) 
and is made up of Jefferson, Bullitt, Oldham, Trimble, Henry, Shelby and 
Spencer Counties.  The Bluegrass ADD contains the second highest number of 
cases appropriate for referral (n=699) and is made up of Anderson, Franklin, 
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Figure 1:  Appropriate Referrals by County 
 
Woodford, Mercer, Boyle, Lincoln, Garrard, Jessamine, Fayette, Scott, Harrison, 
Bourbon, Nicholas, Clark, Madison, Powell, and Estill counties.  Of the 15 ADD’s 
in Kentucky, only 3 have full time, on-site genetic counselors providing cancer 
genetic counseling services (KIPDA, Bluegrass and Northern Kentucky) with an 
additional 6 ADD’s having cancer genetic counseling services available via 
outreach clinics or telemedicine (Cumberland Valley, Gateway, Green River, 
Kentucky River, Lincoln Trail, and Pennyrile).  Of individuals identified in this 
study as being appropriate for referral for cancer genetic counseling services, 
75% (2973/3966) can access these services with a genetic counselor in their 
ADD.  However, even in ADD’s with a genetic counselor, some patients may 
have to drive an hour or more to access services.  The number of appropriate 
cases for referral to genetic services in each ADD are shown in Figure 2. 
 
 
35 
 
Figure 2:  Appropriate Referrals by Area Development District 
 
D. DISCUSSION 
This study represents the first analysis of Kentucky Cancer Registry data for 
identifying cases that would be appropriate for referral to genetic services due to 
being at risk for HBOC or LS.  The study shows that over the four year period 
between 2009-2012, 15,477 (55.06%) of the 28,109 cases of breast, ovarian, 
fallopian tube, colorectal or endometrial cancer in Kentucky were appropriate for 
referral to genetic services based on meeting at least one of the NCCN, EGAPP, 
and ABGC/NSGC criteria examined by this study.   
 Analysis of the Kentucky Cancer Registry data shows that cancer cases 
appropriate for referral to genetic services had overrepresentation of late stage 
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(stage 3 and 4) cancers and cancer deaths when compared to the breast, 
ovarian, fallopian tube, colorectal and endometrial cancers that were not 
appropriate for referral during the study time period.  In cases appropriate for 
referral to genetic services, 33.21% were late stage cancers, and 30.72% of 
cases were from individuals now deceased.  Increasing the number of individuals 
referred for genetic services in the state of Kentucky and then focusing on testing 
the relatives of patients with positive genetic test results through cascade 
screening has the potential to result in more individuals being identified as having 
HBOC and LS before cancer develops.  These Individuals can be offered 
increased screening and preventive services to either prevent a cancer from 
developing or improve the chances that a cancer is diagnosed at the earliest 
possible stage if it were to form.  Based on the information from this study, this 
could subsequently contribute to a decrease in late stage cancers and cancer 
deaths in Kentucky.  A public health focus on increasing genetic counseling and 
testing services for individuals at risk for hereditary cancer syndromes in 
Kentucky would not only contribute to the achievement of national goals in public 
health genetics, such as the Healthy People 2020 goals, but also to state health 
goals.  Recently, Kentucky’s Governor released the KY Health Now goals, which 
call for a reduction in cancer deaths in the state by 10% by 201920.  While 
individuals with a hereditary cancer syndrome such as HBOC and LS will make 
up a small percentage of all cancers diagnosed, identifying them offers an 
opportunity for primary prevention in those at the highest risk to develop cancer.  
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This study also showed that cancer cases identified as appropriate for referral 
to genetic services had a higher proportion of individuals identified as black 
(7.28%) than those cases determined not to be appropriate for referral (6.26%, 
p=0.0005); however, it is important to note that the vast majority of the cases in 
both groups were individuals identified as white.  This finding is likely influenced 
by a number of factors including that African American women are more likely to 
be diagnosed with triple negative breast cancer, which is one of the criteria for a 
case to be a referral.  Furthermore, African American women in Kentucky have a 
higher incidence of invasive breast cancer diagnosis than white women in 
Kentucky21.  There was also a higher proportion of individuals living in 
Appalachian-designated counties in the cases appropriate for referral (28.81%) 
than in those cases determined not to be appropriate for referral (26.69%, 
p=0.0006).  Although these differences between referral and non-referral cases 
are small, but significant, it is important to consider these differences given that 
these represent two underserved populations.  These results can provide 
important information to genetics providers and public health departments in the 
state to further validate the development of programs to increase patient 
identification and referrals.  Previous studies have often shown disparities in the 
access to and use of genetic services by minority groups, specifically African 
Americans22–24.  Few studies have been done to look at genetic counseling in the 
Appalachian population, but a 2007 study did find that living in an Appalachian 
county was not associated with intent to seek cancer genetic services25.  
However, individuals in Appalachian counties likely face a number of barriers to 
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accessing healthcare services such as cost, transportation, child care, obtaining 
time off from work, lower education levels, etc. that could hinder their chances of 
obtaining genetic services.  Furthermore, only 4 of the 54 Kentucky counties 
designated as Appalachian counties by the Appalachian Regional Commission 
(Madison, Whitley, Rowan, and Perry counties) have genetic counseling services 
through outreach or telemedicine.  Given that individuals from Appalachian 
counties were overrepresented in the cases appropriate for referral and currently 
have limited access to genetic counseling services, public health departments 
should look to expand access to genetic counseling in these areas of Kentucky.  
While the differences between groups may change with the use of additional 
criteria for case referral that are not included in this study, additional criteria 
would only increase cases where individuals were African American or living in 
Appalachian counties.  This would further support the need for expanding genetic 
counseling services to underserved populations. 
The identification and referral of patients diagnosed with cancer who are at 
risk for HBOC and LS is important for determining the best plan for additional 
cancer screening and preventive measures in the future, and may also have 
implications for treatment of an individual’s current cancer diagnosis.  
Additionally, relatives of individuals who are identified as having HBOC or LS are 
also at risk for having the condition and its associated increased risk for cancer.  
However, many patients and their relatives who are at risk for HBOC and LS 
remain unaware of their risk and are not appropriately referred to genetic 
services by their medical providers.  One recent study found that physicians 
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correctly identified only 41% of women at high risk for HBOC and referred them 
for genetic counseling and testing26.  A study conducted in Michigan showed that 
in 2012 only an estimated 23.4% of women who had a relative diagnosed with 
breast cancer at or under age 50 had a family member who had undergone 
genetic counseling, and this number was lower for women with a family history of 
ovarian cancer, where only 15.9% reported that a family member had had 
genetic counseling27.   Individuals who are not appropriately referred for genetic 
services represent a missed opportunity to provide preventive services to those 
who are at the highest risk for a future diagnosis of cancer.   
The CDC has proposed methods for state and local health departments to 
use to increase the identification of individuals at risk for HBOC and LS in their 
states28.  One method of improving identification is through bidirectional cancer 
registry reporting.  The analysis and results of this study will provide helpful 
information for Kentucky public health departments and genetics providers for 
taking the first steps towards public health genetics program planning. 
One major obstacle to implementing a population based screening program 
such as bi-directional reporting with the cancer registry is having the genetics 
professional capacity to handle the resulting case load.  Our results indicate that 
a significant number of individuals per year would be appropriate for genetic 
services.  In 2012, the most recent year in the study, 3966 cases were identified 
by this analysis as appropriate for referral.  If even half of these individuals who 
were identified as meeting criteria for genetic services would see a genetic 
counselor, this would be an estimated 1983 patients newly diagnosed with 
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cancer each year who would utilize genetic counseling based on the 2012 data 
from this study.  Based on the National Society of Genetic Counselors (NSGC) 
2012 Professional Status Survey, genetic counselors specializing in cancer see 
an average of 6 new patients per week29.  In order to cover just the patients 
identified in this study for genetic counseling services, 6.4 full time cancer genetic 
counselors would need to be employed in the state.  If we estimate a 10% rate 
for positive genetic test results among these patients, this would result in 
approximately 198 new patients each year identified with HBOC or LS.   
In addition to the index cases identified through bidirectional cancer registry 
reporting or another population-based program, family members of those index 
cases who have positive test results will also need access to cancer genetic 
counseling services.  A Kentucky study that looked at automatic referral for 
certain groups of patients diagnosed with breast and ovarian cancer in one 
healthcare system found that for each index patient found to have a BRCA1 or 
BRCA2 mutation, there was an average of 5.6 first degree relatives who would 
have a 50% risk for also carrying the mutation30.  Similarly, a study looking at 
relatives of index patients who were identified as having LS reported that 249 
relatives of 33 index patients identified with LS underwent testing, or over 7 
relatives per index patient31.  In that study, 109 of these relatives tested positive 
(greater than 3 relatives per index case), and cascade screening could be used 
to continue to systematically screen additional relatives.  Considering the 198 
newly diagnosed cancer patients per year estimated to be found to have HBOC 
and LS using the criteria examined in this study, 1109 first degree relatives at 
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50% risk would be identified (estimating 5.6 first degree relatives per index case), 
many of whom will be unaffected carriers of HBOC or LS and unaware that they 
may have a significantly increased risk for cancer.    
In order to also provide services to these at-risk, first degree family members, 
3.6 additional full time genetic counselors would need to be employed, for a total 
of 10 cancer genetic counselors just to provide services to individuals newly 
diagnosed with breast, ovarian, fallopian tube, colorectal and endometrial 
cancers each year and their first degree relatives.  This model to estimate the 
number of genetic counselors needed to provide services as a result of a 
bidirectional cancer registry reporting program is summarized in Figure 3.   
The number of genetic counselors needed to provide cancer genetic 
counseling in this state will likely far exceed the 10 estimated by this analysis due 
to the limitations of this data analysis resulting in an underestimate of the 
individuals in Kentucky appropriate for cancer genetic services each year.  In 
addition to patient care, genetic counselors would likely also need to increase 
participation in provider and public education in order to prepare for a population 
screening program.  Genetic counselors specializing in cancer also often see 
patients for other hereditary cancer syndromes as well as patients with concerns 
other than hereditary cancer.  The “Find a Counselor” search function on the 
NSGC website and personal communications with genetic counselors in 
Kentucky indicate that there are 10.5 genetic counselors currently providing 
cancer genetic counseling services in the state 32.  These genetic counselors are 
located in the three major cities in Kentucky:  Louisville, Lexington, and 
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Covington and provide outreach services to other areas (clinics and outreach 
summarized in Appendix A).  If population based public health genetics programs 
for the identification of individuals with HBOC and LS are to be successfully 
implemented in the state of Kentucky, it is imperative to support the growth of 
cancer genetic counselors and cancer genetic counseling clinics in the state. 
Analysis of cases by county and ADD indicate that there is a need for cancer 
genetic counseling services throughout the state.  Currently, only 10% of 
Kentucky counties have cancer genetic counseling services available within the 
county.  However, when larger ADD’s are considered, residents in 9 of the 15 
districts encompassing 75% of cases meeting guidelines for referral, have 
access to these services.  If a population based program were to be 
implemented, it would be important for the Kentucky Department for Public 
Health and local health departments in the 6 ADDs without access to cancer 
genetic counseling services to determine the best way to offer services in these 
areas.  Applying the same model for estimating the number of patients and their 
first degree relatives (FDRs) who would access genetic counseling services as 
outlined in Figure 3 for the individual ADDs can help public health leaders identify 
the best placement of additional genetic counselors.   
 
 
Figure 3:  Model for Estimating Genetic Counseling Workforce Needed in KY to 
Provide Services to Patients Identified Through Bidirectional Screening Program 
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The number of estimated patients and FDRs that would present annually in each 
ADD are summarized in Table 5.  Based on this information, an additional 1.17 
full time genetic counselors in Barren River and Lake Cumberland ADDs would 
be able to cover the patients identified through the proposed population based 
program, which improve overall access to services in Kentucky because these 
are the ADDs that currently do not have genetic counseling services with the 
largest number of appropriate cases for genetics referral.  Furthermore, they are 
located in the southern part of the state where services are sparse.  Although 
1983
• 3966 cases identified in 2012 appropriate for referral
• Estimate half of appropriate patients elect to pursue 
genetic services
198
• Estimate a 10% positive rate for HBOC or LS in referred 
patients
1109
• Estimate 5.6 1st degree relatives per positive patient who 
will need genetic services
3092
• Estimated number of patients each year who will need 
genetic services as a result of a public health program 
aimed at increasing identification of at-risk individuals 
(1109 + 1983)
10
• Cancer genetic counselors see an average of 6 patients 
per week (312 patients per year)
• 10 genetic counselors would be required to see these 
patients
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there are fewer cases in the ADDs in the eastern part of Kentucky, the ADDs 
Fivco, Big Sandy, and/or Buffalo Trace would also benefit from the addition of a 
genetic counselor to expand services to this underserved area.  While these 
genetic counselors would cover the patients identified through a bidirectional 
cancer registry screening program, additional patients who meet national 
guidelines not included in this study would also be appropriate for referral, which 
further increases the need for genetic counseling in these areas.  Furthermore, 
given that over 40% of Kentucky residents live in rural areas, alternative methods 
of delivery of services, such as telemedicine, should be considered across the 
state33.  Currently, several genetic counseling centers in Kentucky are offering 
telemedicine services, which could be used as models for setting up additional 
services in the state. 
While bidirectional cancer registry reporting is an important method for 
identifying index cases who have been diagnosed with cancer in families with 
HBOC and LS, it will not identify all individuals who meet national guidelines for 
referral to genetic counseling and/or testing1.  The major limitation of this study is 
that it likely provides a conservative estimate of the number of individuals newly 
diagnosed with these cancers who would be appropriate for a genetics referral 
for evaluation of HBOC or LS.  This is due to this data not including individuals 
who would meet other criteria for referral to genetic services, including having a 
known mutation in the family, being diagnosed with multiple primary cancers, 
being of Ashkenazi Jewish heritage, or having a significant family history of 
cancer 11.  The analysis also did not look at individuals with cancers other than 
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breast, ovarian, fallopian tube, colorectal, and endometrial cancer that are 
associated with HBOC and LS.  Additional cancers that are associated with these 
syndromes include pancreatic, prostate, stomach, small bowel, urinary tract, 
hepatobiliary tract, brain, and other cancers4,34. 
Table 5:  Annual Estimated Patients & First Degree Relatives (FDR) by ADD 
ADD 
Referral 
Cases 2012 
Estimated  
Annual Pts & 
FDR* 
# GCs 
Needed** 
Barren River 243 190 0.61 
Big Sandy 144 112 0.36 
Bluegrass 699 545 1.75 
Buffalo Trace 68 53 0.17 
Cumberland Valley 176 137 0.44 
Fivco 117 91 0.29 
Gateway 83 65 0.21 
Green River 180 140 0.45 
Kentucky River 142 111 0.36 
KIPDA 933 728 2.33 
Lake Cumberland 223 174 0.56 
Lincoln Trail 293 229 0.73 
Northern Kentucky 309 241 0.77 
Pennyrile 158 123 0.39 
Purchase 198 154 0.49 
*Using model outlined in this paper 
 Estimated cases & FDR = ((# cases)(.5) + (#cases)(.5)(.1)(5.6)) 
    **Using model outlined in this paper 
 GCs = (Estimated cases & FDR)/312 
  
Additional groups who were not included in this study are individuals with a 
significant family history of cancer who have not been diagnosed with cancer 
themselves, individuals without cancer with a known mutation in the family, and 
individuals who were diagnosed with breast, ovarian, fallopian tube, colorectal or 
endometrial cancer prior to 2009 or after 2012 who meet criteria for referral to 
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genetic services but were never offered these services.  The latter of these 
groups likely represents a significant number of individuals who are at risk for 
HBOC or LS in Kentucky, given that this study shows that an average of 3869 
patients each year are appropriate for referral using a subset of national 
guidelines.  A recent study of one Kentucky hospital’s cancer center screened 
patient appointment lists to identify women who had been diagnosed with breast 
cancer under age 50 or ovarian cancer at any age who had not previously been 
referred for genetic counseling services30.  In one year, 521 patients were 
identified for referral, with a mean number of years since diagnosis of 5.3 years 
for women with breast cancer and 2.7 years for women with ovarian cancer 30.  
This study illustrates that in addition to the women identified in this data analysis 
who have new diagnoses of breast or ovarian cancer, a significant number of 
individuals with past diagnoses are also appropriate for referral to genetic 
services but have not received them.  This study was conducted at a cancer 
center with an established genetic counseling program, and it is posited that 
hospitals and physician offices that do not employ full time genetic counselors 
would have a higher percentage of patients appropriate for a genetic risk 
assessment who have not been referred.   
The EGAPP recommendations for offering testing for LS to every patient 
diagnosed with colorectal cancer were released in January 20097.  Prior to this 
recommendation, standard practice for identifying patients for referral to genetic 
services for LS involved the use of clinical criteria that relied on family history 
information.  However, as many as 28% of patients with LS would not meet the 
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previously established clinical criteria for patient identification31.  Even after the 
publication of the EGAPP guidelines, uptake of universal screening programs of 
colorectal cancers for LS has been slow.  A study surveying a sample of National 
Cancer Institute-designated Comprehensive Cancer Centers, Community 
Hospital Cancer Programs, and Community Hospital Comprehensive Cancer 
Programs found that 15.9% of responding institutions (11/69) were performing 
universal IHC screening on colorectal tumors in 200935.  A later study that 
surveyed genetic counselors working in a cancer setting found that 27.4% of 
respondents (29/106) indicated that their institution was universally screening 
colorectal tumors for LS as of 201136.  Barriers to universal IHC screening 
implementation were identified and included cost, assembling stakeholders, and 
obtaining approval from appropriate medical staff36.  This delayed implementation 
of screening programs based on the EGAPP guidelines indicate that all 
individuals with colorectal cancer are not currently being offered screening and/or 
testing for LS in Kentucky and that there are likely significant numbers of patients 
diagnosed before the time period examined in this study who would be still be 
appropriate for referral for genetic services to discuss options for evaluation.  
Individuals who are at risk for hereditary cancer syndromes other than HBOC 
and LS would also benefit from referral to genetic services, thus further 
increasing the need for genetic services above what is discussed in this study.  
Finally, while bidirectional cancer registry reporting will identify index cases, 
cascade screening to identify at-risk family members will need to be conducted 
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through other methods. Thus, it is important that providers remain vigilant in 
identifying patients via the ascertainment of a detailed family health history1. 
Another limitation of this study is that Kentucky Cancer Registry data can only 
provide information on who is appropriate for referral to genetic services, but not 
who has been offered or pursued these services.  In fact, there is no state-wide 
data source to obtain this information.  Rather, it would have to be collected from 
individual institutions.   
In conclusion, this study shows that there is a significant, ongoing need for 
cancer genetic counseling services in the state of Kentucky.  At this time, the 
genetic counselors employed in Kentucky would likely not able to effectively see 
the volume of patients that would result from such a program.  Thus, 
simultaneous attention needs to be given to growing the genetic counseling 
workforce and developing public health genetics programs for HBOC and LS.  
Through these programs, Kentucky and other states can ensure that the 
residents are obtaining appropriate referrals to cancer genetic counseling that 
could prove life-saving to themselves and their relatives.   
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CHAPTER 3: 
PAPER 2:  UTILIZING MEDICAID CLAIMS DATA TO ASSESS THE 
USE OF GENETIC TESTING FOR HEREDITARY BREAST AND 
OVARIAN CANCER SYNDROME IN KENTUCKY AND 
CHARACTERISTICS THAT INFLUENCE GENETIC TESTING 
COMPLETION 
A. INTRODUCTION 
B. MATERIALS AND METHODS 
C. RESULTS 
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A. INTRODUCTION 
Breast cancer is the most common cancer diagnosed in women in the U.S. 
and the second leading cause of cancer death in women1.  Although far less 
common, ovarian cancer is the fifth leading cause of cancer death in women1.  A 
small, but significant subset of breast and ovarian cancers are due to Hereditary 
Breast and Ovarian Cancer (HBOC) syndrome, which is a genetic condition that, 
most often, is associated with mutations in the BRCA1 and BRCA2 genes.  
HBOC due to BRCA1 and BRCA2 mutations causes increased lifetime risks for 
breast (up to 90%), ovarian (up to 62%), and other cancers2.  It is estimated that 
approximately 5% of female breast cancer (9.5% of breast cancers diagnosed 
under age 50), 25% or more of male breast cancers, and up to 18% of ovarian 
cancers are due to HBOC 3–6.   
Individuals who have been diagnosed with cancer and found to have a 
BRCA1 or BRCA2 mutation are at increased risk for developing a second 
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cancer.  Results of genetic testing can provide important information for the 
surgical management of high risk women newly diagnosed with breast cancer7–
11.  Genetic testing also has important implications for the medical treatment of 
cancer, especially with the recent FDA approval of Lynparza (olaparib) for the 
treatment of women with a BRCA1 or BRCA2 mutation and ovarian cancer12.  
Furthermore, it is preferable to complete BRCA1 and BRCA2 genetic testing in a 
family first in an individual who has already been diagnosed with cancer13.  The 
American Society of Clinical Oncology recommends that patients diagnosed 
with cancer who meet specific criteria be offered genetic testing for hereditary 
cancer syndromes including HBOC, and the Commission on Cancer requires 
that genetic counseling and testing services be available to patients either on-
site or through referral as part of their accreditation program14,15.       
After an index case of HBOC is identified in a family, other relatives can 
typically be identified who are at risk for carrying the same genetic mutation and 
increased risk for cancer.  Testing can then systematically be offered to these 
relatives to identify high-risk individuals who would benefit from increased 
screening and prevention for breast and ovarian cancer.  Interventions available 
for individuals found to have a BRCA1 or BRCA2 mutation include prophylactic 
removal of the breasts and/or ovaries, earlier and additional screening for breast 
cancer, and taking medications that can reduce the risk of cancer2,4.  These 
interventions have been shown to be effective at reducing cancer risk and/or 
diagnosing a cancer earlier in individuals with BRCA1 and BRCA2 associated 
HBOC.     
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There is extensive literature on disparities in the referral of patients for genetic 
counseling and/or testing and the uptake of genetic testing, which has been a 
concern since testing was first implemented.  Many of these studies have 
focused on racial disparities in genetic testing for HBOC.  An early study by 
Armstrong, et al. found that Caucasian women had 4.1 times the odds of 
undergoing genetic counseling for BRCA1 and BRCA2 than non-Caucasian 
women16.  A case-control study of women with a family history of breast or 
ovarian cancer undergoing genetic counseling between 1999 and 2003 
determined that African American women were significantly less likely to have 
genetic counseling than Caucasian women even after controlling for other 
factors that affect uptake (adjusted OR=0.28, 95% CI 0.09-0.89)17.  However, a 
study of women referred for genetic counseling between 2001 and 2008 found 
no difference in the uptake of genetic testing by race among individuals who 
received genetic counseling18.  Continued documentation of racial disparities in 
access to genetic counseling for hereditary cancer syndromes led Hall et al. to 
state that, “Increasing testing access and volume in racial/ethnic minority and 
underserved populations must be a national priority if mounting disparities in 
genetic testing utility and utilization are to be eliminated.”19  Other patient socio-
demographic factors found to influence uptake of genetic counseling or testing 
include age, referral source, marital status, increased breast cancer risk, and 
knowledge of genetics16,20,21. 
Provider barriers can also affect whether a patient appropriate for genetic 
counseling and/or testing is referred for genetic services.  Awareness of genetic 
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services has been found to be essential to provider referral, and many studies 
have called for increased education of physicians about genetic counseling and 
testing for hereditary cancer22–24.  One study of a national sample of primary and 
tertiary care physicians found that referrals were highest for patients who 
initiated the conversation about genetic risk for breast and ovarian cancer 
themselves (OR 5.52; 95% CI, 3.97-7.67)22.  Concerns about insurance 
coverage for testing and the fear of genetic discrimination have also traditionally 
impacted physician referral as illustrated in multiple studies that were conducted 
before and after the Genetic Information Nondiscrimination Act (GINA) was 
passed in May 200822–25.   
Early studies of the referral and uptake of BRCA1 and BRCA2 genetic testing 
indicated that lack of provider knowledge and lack of clinical guidelines for 
referring patients were barriers to patients receiving this testing23,24,26.  More 
recently, several organizations have published evidence-based guidelines for 
identifying individuals appropriate for genetic risk assessment, counseling, and 
testing.  The National Comprehensive Cancer Network (NCCN) has issued 
guidelines for identifying individuals diagnosed with breast, ovarian, and 
fallopian tube cancers who are appropriate candidates for genetic testing 2.  The 
American College of Medical Genetics (ACMG) and National Society of Genetic 
Counselors (NSGC) have issued joint guidelines for identifying individuals with a 
variety of hereditary cancer syndromes, including HBOC, and the U.S. 
Preventive Services Task Force (USPSTF) published guidelines specifically for 
identifying unaffected, at-risk women appropriate for genetic counseling27.  
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However, many individuals with HBOC are not appropriately referred and 
remain undiagnosed despite these national guidelines for patient 
identification25,28,29. 
Genetic testing for HBOC has been identified by the Centers for Disease 
Control and Prevention (CDC) as a Tier 1 Genomic Application based on 
analytic validity, clinical validity, clinical utility and existing evidence-based 
guidelines indicating that the use or test is ready for population-based 
implementation30,31.  Recently, the CDC has released a toolkit for local and state 
health departments to help these entities implement programs for the education, 
identification, and screening of individuals at increased risk for HBOC and other 
Tier 1 Genomic disorders 32.  As states begin the process of developing and 
implementing these programs, special attention should be paid to disparities in 
genetic counseling and testing specific to the state.  While previous studies 
certainly provide a starting point for considering and addressing disparities, the 
majority of these studies looking at disparities in genetic counseling and testing 
for HBOC based on patient socio-demographic factors have been institution 
specific, and studies of provider-perceived barriers have largely been conducted 
through institutional or national surveys22–24,26.   
Utilizing data already being collected by states can be helpful in both 
assessing need for genetic counseling and testing services and in identifying 
state-specific disparities.  In this study, Kentucky Medicaid Claims data is 
utilized to identify genetic testing disparities in an already underserved 
population.  The use of this data set allows for assessment of disparities when 
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insurance coverage is not an issue as Kentucky Medicaid has covered genetic 
testing in full for patients meeting clinical criteria for HBOC over the time period 
included in this secondary data analysis.  Furthermore, genetic testing of the 
BRCA1 and BRCA2 genes has been available commercially in the U.S. for 
nearly 20 years.  This testing had been performed exclusively by Myriad 
Genetics, Inc. until June 2013 when the Supreme Court decision of Association 
of Molecular Pathology, et al v. Myriad Genetics, Inc., et al. invalidated some of 
the patents held by Myriad on the BRCA1 and BRCA2 genes, prompting other 
laboratories to begin offering testing33.  A single laboratory offering this testing 
simplifies the search for individuals who have undergone testing in the Medicaid 
Claims data set.  Utilizing a secondary data source also represents a cost-
effective way for an initial analysis to be completed in a state, such as Kentucky, 
where there is no funding or dedicated staff for public health genetics and 
genomics outside of newborn screening.   
The aims of the current study are to 1) determine how many individuals with 
Kentucky Medicaid diagnosed with breast, ovarian, and fallopian tube cancer 
who were appropriate for genetic counseling and testing for HBOC received 
genetic testing; and 2) determine the socio-demographic and provider factors 
that predict receipt of genetic testing.  Information about the factors that predict 
whether a particular patient receives genetic testing can then be used by public 
health and genetics professionals to begin to address the particular disparities in 
access to genetic counseling and testing services present in Kentucky.  To our 
knowledge, this is the first study utilizing state Medicaid data to conduct a needs 
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assessment for cancer genetic counseling and testing services and identify 
state-specific disparities in access to these services.   
B. METHODS 
This study consists of a secondary data analysis of Kentucky Medicaid data 
for individuals diagnosed with breast (including male breast), ovarian, or fallopian 
tube cancer from 2009-2012.  Data were obtained from the Kentucky Medicaid 
Claims Database using ICD-9 codes corresponding to these diagnoses of 
cancer.  ICD-9 codes included 174.* (malignant neoplasm of female breast), 
175.* (malignant neoplasm of male breast), 183.0 (malignant neoplasm of ovary), 
and 183.2 (malignant neoplasm of fallopian tube). The data set was obtained 
after University of Kentucky and the Kentucky Cabinet for Health and Family 
Services IRB approval. 
The following NCCN criteria for referral to genetic services for HBOC were 
used to determine which individuals included in the Kentucky Medicaid data set 
would be appropriate candidates for referral 2: 
 Women diagnosed with breast cancer ≤ 50y 
 Women diagnosed with ovarian or fallopian tube cancer 
 Men diagnosed with breast cancer at any age 
Given that this is a cross-sectional data set, information was not available on 
the age at diagnosis with cancer.  Thus, women diagnosed with breast cancer 
included in the data set were considered appropriate for genetic testing if their 
youngest age at the time of a claim in the database was age 50 or younger.  All 
individuals diagnosed with ovarian, fallopian tube, and male breast cancer were 
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considered appropriate for referral.  CPT codes that designate genetic testing 
were used to determine those individuals in the subset of records identified as 
being appropriate for genetic counseling and/or testing who actually were tested.  
These CPT codes included: 83891 (isolation or extraction of highly purified 
nucleic acid), 83898 (amplification of patient nucleic acid), 83904 (mutation 
identification by sequencing), 83909 (separation by  high resolution technique), 
and 83912 (interpretation and report).  In 2012, additional CPT codes were 
introduced for genetic testing of the BRCA1 and BRCA2 genes, including: 81211 
(BRCA1, BRCA2 gene analysis; full sequence analysis and common 
duplication/deletion variants in BRCA1), 81212 (BRCA1, BRCA2 gene analysis; 
185delAG, 5385insC, 6174delT variants (the three common mutations found in 
the Ashkenazi Jewish population)), 81213 (BRCA1, BRCA2 gene analysis; 
uncommon duplication/deletion variants), 81214 (BRCA1 gene analysis; full 
sequence analysis and common duplication/deletion variants), 81215 (BRCA1 
gene analysis; known familial variant), 81216 (BRCA2 gene analysis; full 
sequence analysis), and 81217 (BRCA2 gene analysis; known familial variant).  
These were also used to determine individuals who had undergone genetic 
testing in 2012.  Although Healthcare Common Procedure Coding System 
(HCPCS) codes were introduced for genetic testing during the time period 
included in this secondary data analysis, they did not appear in the data set and 
as a result were not used to identify individuals undergoing genetic testing.  
Variables included in the data set received from the Kentucky Medicaid 
Claims database and utilized in this study were: Medicaid ID number, age at 
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claim, gender, ethnicity, patient geographical coordinates (latitude/longitude), 
billing provider, place of service, category of service, provider specialty, 
procedure codes, date of claim, ICD-9 Codes, patient survival, and presence of 
CPT codes for genetic testing (83891, 83898, 83904, 83909, 83912, 81211, 
81213).  The Medicaid claims data set contained multiple entries per Medicaid 
recipient, and information was condensed to create one entry per individual 
meeting the above stated criteria for genetic testing.  For individuals who had 
conflicting information coded into the database for fixed characteristics, such as 
race, sex, and ethnicity, the description that occurred most commonly in the data 
set was used and applied to the unique entry for that individual.  For 
demographic information that was claim dependent such as including whether 
services were received in an Appalachian county, final entries were coded based 
on where the majority of services were received.  Age was determined using the 
age at claim for the earliest claim in the database for any given individual. Cancer 
type was determined using ICD-9 codes included with each claim.  The database 
contained the first four ICD-9 codes per claim, and cancer type was determined 
first by the primary diagnosis code, and then by secondary diagnosis codes if 
one of the ICD-9 codes examined in this study was not present.  Data cleaning 
identified several individuals with both breast and ovarian (or fallopian tube) 
cancers, and the unique entry for those Medicaid ID numbers were coded based 
on the first cancer to appear in the database.   
Basic descriptive statistics are reported for the data subset of individuals 
determined to be appropriate for referral to genetic services.  Independent 
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sample t-test (for continuous variables) and Chi-square tests (for categorical 
variables) were used to determine differences between individuals who did and 
did not receive genetic testing.  Logistic regression was then performed to 
evaluate which demographic and provider variables were associated with the 
outcome variable of whether an individual received genetic testing while 
controlling for other variables in the model. All independent variables of interest 
were included in the first model, and the final model was obtained by excluding 
some variables that were not significant.  Breslow-Day tests were used to 
determine possible variable interactions.   
Multiple diagnostics were assessed for the final model including 
convergence criterion, the likelihood ratio to determine if the overall model was 
significant, Hosmer and Lemeshow Goodness of fit test to determine if the fitted 
model was an adequate fit, and the r-square value. 
 The locations of cancer genetic counseling services were obtained 
through key informant interviews with genetic counselors in the state of 
Kentucky. All statistical analyses were completed using SAS v.9.3 and R version 
3.1.3. 
C. RESULTS 
A total of 3144 unique individuals included in the Kentucky Medicaid Claims 
Database between 2009 and 2012 were identified as meeting criteria for genetic 
testing for HBOC based on the criteria outlined previously.  Of these individuals, 
1849 had female breast cancer and a claim in the database at or under age 50.  
There were 74 individuals diagnosed with male breast cancers included in the 
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data set and 1221 individuals diagnosed with ovarian or fallopian tube cancers.  
Of note, 34 individuals in the data set had ICD-9 codes for both female breast 
and ovarian/fallopian tube cancer.  For the purpose of this study, which utilized 
only one observation per individual included in the database, these individuals 
had their cancer type classified based on which diagnosis appeared on the 
earliest claim.  Of these 3411 unique individuals, 241 (7.7%) had a claim for 
genetic testing between 2009 and 2012.  These results are summarized in Table 
1. 
Table 1:  Appropriate Referrals and Genetic Testing by Cancer Type 
  
Appropriate 
Referral Genetic Testing 
  (n=3144) (n=241) 
Breast 
(Female) 1849 226 (12.2%) 
Breast (Male) 74 0 (0%) 
Ovarian/FT 1221 15 (1.2%) 
 
Given that genetic testing is often associated with multiple CPT codes for one 
test, the 241 individuals who had genetic testing claims between 2009 and 2012 
had a total of 1402 claims with one of the CPT codes for genetic testing.  Of 
these 77.03% of the claims were paid.  Myriad Genetic Laboratories was the 
provider for the majority of claims (87.23%) with other claims being filed by 
hospitals and other independent labs. 
The average age at the time of claim of individuals who were appropriate for 
genetic testing is 48.46 years (sd=13.31).  Individuals who had a claim for 
genetic testing were statistically significantly younger than individuals who were 
appropriate for genetic testing but did not have a claim between 2009 and 2012 
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for this testing (t=13.63, p<0.0001).  When looking specifically at average age by 
cancer type, women diagnosed with breast cancer who had testing were 
statistically significantly younger than women who did not have testing (t=4.6, 
p<0.0001).  A significant difference in mean age was not found for women 
diagnosed with ovarian or fallopian tube cancer (t=1.61, p=0.1087).  These 
results are summarized in Table 2. 
Table 2:  Mean Age of Patient by Cancer Type and Genetic Testing 
  
Mean Age (SD) 
No Genetic Testing Genetic Testing t-value p-value 
All Cancer Types 49.05(13.50) 41.37 (7.83) 13.63 <0.0001 
Breast (Female) 43.01 (6.80) 40.79 (6.60) 4.6 <0.0001 
Ovarian/FT 56.72 (15.95) 50.07 (16.28) 1.61 0.1087 
 
Study demographics show that 83.11% of individuals in this data set who 
were identified as appropriate for referral for genetic testing are white, 9.73% are 
black and 0.97% are of other race.  Of the individuals appropriate for referral to 
genetic services who identified as white, 7.85% had a claim for genetic testing, 
and 10.13% of individuals who were appropriate for referral and identified as 
black had a claim for genetic testing.  Of individuals found to be appropriate for 
referral to genetic testing, 26.40% received the majority of their services between 
2009 and 2012 in Appalachian counties, 71.02% received the majority of their 
services in Non-Appalachian counties, and 2.54% only had claims from out of 
state. Chi-square testing indicated a statistically significant difference between 
Appalachian county designation and genetic testing (ᵡ2=86.66, p<0.0001).Of the 
830 individuals in this data set who received the majority of services in 
Appalachian counties, 59 (7.10%) had a claim for genetic testing compared to 
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6.90% (154 of 2233) of individuals who received the majority of services in non-
Appalachian counties.  Individuals who had a claim from a gynecologist were 
more than twice as likely to receive genetic testing (15.2%) as those who did not 
see a gynecologist (7.4%).  Individuals who saw an oncologist during the study 
period were nearly 3 times more likely to receive genetic testing (16.4%) as those 
who did not see an oncologist (5.7%).  Distance from a genetic counseling clinic 
was calculated using longitude and latitude data of the patients and the cancer 
genetic counseling clinics in Kentucky.  Distance to the closest clinic was then 
categorized and reported for just the full-time cancer genetic counseling clinics 
(Main) and for all cancer genetic counseling clinics (including outreach and 
telemedicine clinics).  These data show that the majority of individuals who had 
genetic testing lived within 50 miles of a main cancer genetic counseling clinic 
(41.91%).  However, chi-square analysis did not show a statistically significant 
difference between distance from genetic counseling clinics and genetic testing. 
All study demographics and descriptive statistics are summarized in Table 3. 
Table 3:  Patients for Genetic Services Referral Demographics 
    Genetic Testing 
  Total No Yes 
  (n=3144) (n=2903) (n=241) 
Ageⱡ   
     Mean (sd) 48.46 (13.31) 49.05(13.50) 41.37 (7.83) 
Sex*   
     Male 106 (3.37%) 106 (3.65%) 0 (0%) 
     Female 3038 (96.63%) 2797 (96.35%)  241 (100%) 
Race* 
     White 2613 (83.11%) 2408 (82.95%) 205 (85.06%) 
     Black 306 (9.73%) 275 (9.47%) 31 (12.86%) 
     Other 31 (0.97%) 30 (1.03%) 1 (0.41%) 
     Not Reported 194 (6.17%) 190 (6.54%) 4 (1.66%) 
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Ethnicity* 
     Non-Hispanic 2933 (93.29%) 2697 (92.90%) 236 (97.93%) 
     Hispanic 17 (0.54%) 16 (0.55%) 1 (0.41%) 
     Not Reported 194 (6.17%) 190 (6.55%) 4 (1.66%) 
Appalachian County* 
     Yes 830 (26.40%) 771 (26.56%) 59 (24.48%) 
     No 2233 (71.02%) 2079 (71.62%) 154 (63.90%) 
     Out of state 80 (2.54%) 52 (1.79%) 28 (11.62%) 
Distance from Genetic Counseling Clinic (Main)   
     ≤ 50 miles 1371 (43.61%) 1270 (43.75%) 101 (41.91%) 
     51-100 miles 1042 (33.14%) 962 (33.14%) 80 (33.20%) 
     101-150 miles 561 (17.84%) 517 (17.81%) 44 (18.26%) 
     >150 miles 170 (5.41%) 154 (5.30%) 16 (6.64%) 
Distance from Genetic Counseling Clinic (Any) 
     ≤ 50 miles 2806 (89.25%) 2588 (89.15%) 218 (90.46%) 
     51-100 miles 331 (10.53%) 309 (10.64%) 22 (9.13%) 
     101-150 miles 3 (0.10%) 2 (0.07%) 1 (0.41%) 
     >150 miles 4 (0.13%) 4 (0.14%) 0 (0%) 
Vital Status* 
     Alive 2244 (71.37%) 2037 (70.17%) 207 (85.89%) 
     Deceased 900 (28.63%) 866 (29.83%) 34 (14.11%) 
Claim from Gynecologist* 
     Yes 105 (3.34%) 89 (3.07%) 16 (6.64%) 
     No 3039 (96.66%) 2814 (96.93%) 225 (93.36%) 
Claim from Oncologist* 
     Yes 579 (18.42%) 484 (16.67%) 95 (39.42%) 
     No 2565 (81.58%) 2419 (83.33%) 146 (60.58%) 
Year First in Database* 
     2009 1322 (42.05%) 1277 (43.99%) 45 (18.67%) 
     2010 646 (20.55%) 598 (20.60%) 48 (19.92%) 
     2011 607 (19.31%) 528 (18.19%) 79 (32.78%) 
     2012 569 (18.10%) 500 (17.22%) 69 (28.63%) 
    
ⱡ t-test shows statistically significant difference in means between genetic testing groups (p 
<0.05) 
* Chi-square analysis shows statistically significant association between variable and Genetic 
Testing (p < 0.05) 
 
Logistic regression was performed to assess which independent variables of 
interest contributed to whether recipients of Kentucky Medicaid received genetic 
testing.  The results of this analysis showed that a number of variables were 
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associated with the outcome variable of whether individuals had received genetic 
testing.  Of note, increasing age was associated with a decrease in the odds of 
an individual having genetic testing with a 13.2% decrease in the odds of having 
genetic testing for every 5 year increase in age (p<0.0001).  Individuals 
diagnosed with female breast cancer had 9.137 times the odds of having genetic 
testing when compared to those diagnosed with ovarian or fallopian tube cancers 
(p<0.0001).  Patients who saw a gynecologist during the time span of the study 
had 1.81 times the odds of having genetic testing than patients who did not see a 
gynecologist (p=0.0083) after controlling for other variables in the model.  
Patients who saw an oncologist during the time span of the study had 3.599 
times the odds of having genetic testing than those who did not see this type of 
specialist (p<0.0001).  In this sample, we did not find a statistically significant 
difference in genetic testing by race.   
Several potential interaction variables were identified utilizing Breslow-Day 
tests, and included Appalachian*gynecology, Appalachian*oncology, and vital 
status*cancer type.  When included in the model, these interaction variables 
caused a quasi-separation of data points, and as a result were ultimately 
excluded from the final regression model.  The odds ratios and confidence 
intervals for variables included in the final regression model are summarized in 
Table 4.   
Diagnostic tests for the logistic regression were used to determine the fit of 
the model.  The measure of deviance indicated that the model was a good fit 
(p=1.0) but the Pearson Goodness of Fit indicated that the model may not be a 
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good fit (p=0.0114).  The R-squared value indicates that the model explains 
22.06% of the variance in the outcome variable, genetic testing.  Convergence 
criterion were satisfied. 
Table 4:  Logistic Regression Results for Genetic Testing Outcome 
Parameter 
Odds 
Ratio 
95% Confidence 
Limits p-value 
Age 0.972 0.960-0.985 <0.0001 
Cancer Type 
     Ovarian/FT ref     
     Female Breast 9.137 6.155-13.562 <0.0001 
     Male Breast <0.001 <0.001 to >999.999 0.9765 
Race 
     White ref     
     Black 0.873 0.633-1.206 0.4102 
     Other 0.276 0.065-1.170 0.0807 
     Not Reported 0.309 0.148-0.646 0.0018 
Year First in Database 
     2009 ref     
     2010 2.611 1.931-3.564 <0.0001 
     2011 5.075 3.811-6.759 <0.0001 
     2012 5.212 5.212-3.871 <0.0001 
Claim from a Gynecologist 
     No ref     
     Yes 1.816 1.166-2.828 0.0083 
Claim from an Oncologist 
     No ref     
     Yes 3.599 2.886-4.488 <0.0001 
Appalachian County 
     No ref     
     Yes 1.24 0.973-1.580 0.082 
     Out of State 9.355 6.137-14.260 <0.0001 
 
D.  DISCUSSION 
 This study was the first to use Medicaid Claims data to determine the use 
of genetic testing among individuals who have been diagnosed with breast, 
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ovarian, and fallopian tube cancers in Kentucky.  This data set was chosen 
because there is currently no data set at the state level that includes information 
on whether individuals who are appropriate for referral to genetic services are 
actually referred and receive those services.  While this data set does not provide 
complete information on individuals receiving genetic testing, it does provide a 
limited view into the use of genetic testing in Kentucky.  Furthermore, this data 
represents a sample of individuals in the Commonwealth of Kentucky who would 
have had full coverage for genetic testing because Kentucky Medicaid provides 
full coverage for genetic testing given that a patient meets nationally established 
clinical criteria for testing.  This was the case during the entire study period, thus 
eliminating insurance coverage as a confounding factor that may be important to 
consider in other data sets.   
The study shows that between 2009 and 2012, 3144 Medicaid recipients 
who had been diagnosed with breast, ovarian or fallopian tube cancer met 
clinical criteria for referral for genetic counseling and testing.  Of these, 214 
(7.7%) actually had a claim for genetic testing over the same time period.  This 
study certainly shows room for improvement in patient referral to and uptake of 
genetic testing services in the state of Kentucky among Medicaid recipients.  
However, this number is likely an underestimate of the individuals who received 
genetic testing.  Because cross-sectional data was used, it is likely that some 
individuals included in this data set underwent genetic testing either prior to or 
after the study period.  In addition, a number of individuals may have been 
referred for genetic services by their healthcare provider, but decided not to 
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proceed with genetic counseling and/or genetic testing after the referral.  
Furthermore, individuals utilizing Medicaid are often not continuously enrolled, 
and a proportion of those identified in this data set as being appropriate for 
referral for genetic testing may have had genetic testing while uninsured or on a 
health insurance plan other than Medicaid.   
Despite the likelihood that the number of individuals appropriate for 
genetic services who received genetic testing shown by the results of this study 
is an underestimate, the data does show that a significant number of individuals 
are not undergoing the appropriate genetic testing.  Genetic testing for HBOC 
and other hereditary cancer syndromes not assessed in this study is important 
for creating a future cancer screening and prevention plan for individuals who 
have already been diagnosed with cancer.  Individuals who are found to have 
HBOC have a significantly increased risk of developing a second cancer in the 
future.  However, there are surgical, screening, and medication options available 
for those who are found to have HBOC that can either prevent a second cancer 
from forming or increase the chances that cancer is found at an early stage if it 
were to develop.  More recently, genetic test results have also become important 
to treatment planning of individuals with a new diagnosis of cancer, specifically 
related to surgical interventions for women with breast cancer and treatment with 
PARP (poly ADP ribose polymerase) inhibitors in women diagnosed with ovarian 
cancer.  In addition, genetic testing is important in cancer prevention in the family 
members of an index case, and it represents an important method of primary 
cancer prevention among those most at risk.   
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 The logistic regression analysis completed in this study found that a 
number of variables were associated with the genetic testing outcome.  These 
variables included patient age (earliest age of patient recorded in the data set) 
cancer type, year the patient first appears in the database, and having a claim 
from a gynecologist and/or oncologist.  For every 5 years of increased in patient 
age, there was a 13.2% decrease in the odds that that person had had genetic 
testing (p<0.0001).  One explanation for this may be that providers are more 
likely to think of genetic counseling services for women who are very young at 
the time of diagnosis, but may be less likely to refer patients who are diagnosed 
closer to age 50 even though they still meet criteria and should be referred.  
Furthermore, women with breast cancer had greater than 9 times the odds of 
having had genetic testing than women diagnosed with ovarian or fallopian tube 
cancer (p<0.0001).  This could be due to a number of factors including 
physicians being more knowledgeable about the benefit of genetic testing for 
women with breast cancer.  Furthermore, women with ovarian cancer are 
typically diagnosed at later stages of cancer development, and physicians may 
be less likely to refer and/or patients less likely to follow through with the referral 
due to other health concerns.  Individuals who had seen a gynecologist or 
oncologist during the 4 year study period had significantly higher odds of having 
genetic testing than those who did not see these physician specialties.  However, 
only 3.34% (105/3144) of those appropriate for a referral saw a gynecologist, and 
only 18.42% (379/3411) saw an oncologist.  These logistic regression results 
may indicate that Kentucky providers need to be provided with information 
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regarding referral to cancer genetic counseling services.  Based on the results of 
this study, future educational efforts in Kentucky may have more of an impact if 
they were focused on primary care and other specialty providers. 
 Of note, this study did not find a statistically significant association 
between patient race and having a claim for genetic testing during the study 
period.  Although a number of studies have found racial disparities in genetic 
counseling and testing16,17, at least one other more recent study did not find this 
association18.  The current study provides further information regarding race and 
genetic testing, and indicates that this disparity, though seen early in the 
availability of genetic testing for hereditary cancer syndromes, may be 
decreasing over time.  However, this finding may also be due in part to race not 
being reported for 6.17% of individuals included in this sample and/or that the 
population of Kentucky is predominantly composed of individuals who identify as 
white. Additional studies will need to be completed in order to determine if 
disparities in genetic testing due to race are decreasing.   
 This study does show that an individual’s odds of having genetic testing 
improve in the later years included in the data set.  While this shows that 
appropriate patients are likely currently being referred more often to genetic 
services, the percent of individuals receiving genetic testing remains concerning.  
There are a number of reasons why such a small percentage of appropriate 
patients for referral to genetic services are actually undergoing genetic testing.  
For example, patients may not be referred because providers are unaware of 
availability of cancer genetic counseling services.  Previous studies have shown 
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that lack of provider knowledge about the availability of cancer genetic 
counseling services is a barrier to care, even when the genetic counseling 
service is located within a provider’s organization22–24.   
Correspondence with cancer genetic counseling clinics in Kentucky 
indicate that only 12/120 (10%) counties in Kentucky have cancer genetic 
counseling services being offered in the county either directly or through 
outreach and/or telemedicine.  Currently, Kentucky does not maintain an active 
list of cancer genetic counseling services in the state, which means that 
providers must take extra steps to determine where to refer appropriate patients.  
As information on cancer genetic counseling clinics was collected as part of this 
study, a list will be submitted to the Kentucky public health genetics coordinator.  
Additional studies will be needed in order to determine if lack of knowledge about 
genetic counseling services is a barrier to Medicaid providers in the state.  If this 
is the case, then state-level educational programs for Medicaid providers and 
development of resources to aid in education and physician referral need to be 
considered by the Kentucky Department for Public Health and state genetics 
providers.   
Another potential barrier to referral may be lack of knowledge about 
insurance coverage of testing.  Even though Medicaid has covered genetic 
testing of the BRCA1 and BRCA2 genes for a number of years, this fact may not 
be widely known outside of providers who regularly provide genetic services or 
refer to genetic services.  Given that this dataset is looking at an underserved 
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population, cost of genetic testing would likely be a concern of both providers and 
patients when considering referral or following through on a referral.   
Focusing on increasing referrals among the Kentucky population receiving 
Medicaid will only grow in importance in the future given the 2014 Medicaid 
expansion in Kentucky.  As stated previously, additional educational programs 
should be considered for providers in the state to increase the awareness of 
genetic counseling services and clinical guidelines for referral.  This study also 
provides evidence to support the implementation of strategies outlined in the 
CDC’s Tier 1 Genomic Applications Toolkit for increasing the number of patients 
who are identified as appropriate for genetic counseling.  Strategies suggested in 
the toolkit that could be considered by Kentucky include bidirectional cancer 
registry reporting, which is a process where the cancer registry uses national 
guidelines for referral of individuals diagnosed with cancer to genetic counseling 
services to identify cases that should be referred and then sending this 
information as well as educational materials on hereditary cancer syndromes 
back to reporting institutions to help in patient identification.  Other strategies 
could include evaluating the policies of Medicaid insurance providers to 
determine if clear guidelines for coverage of genetic testing are in place and 
readily available to healthcare providers and developing methods to assess the 
awareness and use of genetic testing among the general population in Kentucky, 
such as developing new questions for the state Behavioral Risk Factor 
Surveillance System (BRFSS) about genetic testing.   
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 The limitations of this study are due mainly to the data set used for this 
secondary data analysis.  First, the Kentucky Medicaid Claims database is only 
as complete and as accurate as the information being submitted by providers.  It 
is possible that there are claims for genetic testing for Medicaid members that 
are not included in the data set requested.  During the data cleaning process, a 
number of entries were found with misinformation (for example, a patient is 
coded as being female when all other claims for the same individual indicate that 
the person is a male).  Considerable effort to correct these type of entries was 
made, but misinformation may still exist in the data set.  As stated previously, 
there are a number of factors that make it likely that the estimate of the number 
of appropriate individuals for genetic referral who received genetic testing (7.7%) 
is an underestimate.  However, the number of individuals appropriate for referral 
to genetic services for HBOC is also likely an underestimate.  The three clinical 
criteria used in this study to identify appropriate patients (individuals diagnosed 
with breast cancer under age 50, all individuals diagnosed with male breast 
cancer, and all individuals diagnosed with ovarian or fallopian tube cancer) will 
miss a number of members who are appropriate for genetic services including 
those with a family history of breast, ovarian, or other cancers, those with a 
known BRCA1 and BRCA2 mutation in the family, those with triple negative 
breast cancer diagnoses and those diagnosed with multiple cancers.  However, 
there is currently no state-level data that contains the type of information needed 
to identify some of these individuals who are appropriate for referral, and utilizing 
this Medicaid data provides a useful first step to assessing the need for 
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increased education, programs, and genetic services to ensure that at-risk 
individuals are being referred to cancer genetic services.      
 While this study provides useful information for a Kentucky state-wide 
needs assessment regarding cancer genetic counseling and testing, it only 
addresses the issue in one set of individuals.  Additional research will need to be 
done to ascertain the use of genetic testing by individuals with insurance 
coverage from other companies.  This will provide a more comprehensive picture 
of genetic testing in Kentucky and would be useful for future program 
development by the Kentucky Department of Public Health and genetics 
providers.  The results of this study will not be generalizable to all other states 
given the specific and limited nature of the data used for this secondary data 
analysis, but may be generalizable to states with similar population 
demographics and availability of genetic counseling services.  Other researchers 
can use this study as an example to begin examining the use of cancer genetic 
counseling services in their own states.  It is only through the generation of 
evidence that the need for increased education and programming for public 
health genetic issues will make its way to the agenda of healthcare facilities, 
policy makers, and public health departments.   
 In conclusion, this study shows that there is a significant difference 
between the number of individuals who are appropriate for referral to cancer 
genetic services and those who actually receive services.  This study has 
identified potential variables that are associated with increased odds of a patient 
receiving genetic testing.  This information can be used to begin developing a 
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plan for programming addressing public health genetics issues in the state of 
Kentucky in the future.  The CDC has released information and resources for 
states on program implementation that can help improve the health of state 
citizens by disease prevention and early detection.  This study demonstrates the 
impact that implementing programs to increase referrals of appropriate 
individuals for cancer genetic services can have on cancer prevention and early 
detection in Kentucky. 
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CHAPTER 4 
IMPLICATIONS FOR PUBLIC HEALTH 
A. INTRODUCTION 
B. SUMMARY OF RESULTS 
C. CONCLUSIONS 
D. IMPLICATIONS 
E. RECOMMENDATIONS 
 
A. INTRODUCTION 
 The need for state policies and programs in public health genetics 
and genomics is expanding beyond the traditional role of providing 
newborn screening and the associated follow-up of abnormal screen 
results.  There is significant evidence that genetic testing for predisposition 
diseases across the lifespan can prevent serious illness and even 
premature death in individuals who are found to have a genetic mutation 
that puts them at high risk for disease.  In the field of cancer genetics, 
genetic testing for Hereditary Breast and Ovarian Cancer syndrome 
(HBOC) and Lynch syndrome (LS) has been shown to provide beneficial 
information for affected individuals who can then take steps to reduce the 
risk for cancer associated with one of these syndromes.  Despite this 
evidence, the majority of individuals with these two conditions remain 
unaware of their risk because they have not been referred for genetic 
counseling and/or testing.   
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In order to bring attention to the importance of utilizing evidence- 
based testing for hereditary cancer syndromes and other inherited 
conditions, the CDC has released information ranking genetic tests and 
family history applications for genetic diseases based on the level of 
available evidence.  The CDC has also developed resources to help state 
and local health departments implement policy and programs for 
addressing those diseases with the highest ranking, or Tier 1 Genomic 
Applications.  Several pioneer states have been working for over a decade 
to improve awareness of and access to services for inherited cancer, 
cardiac, and other syndromes.  These states, however, have been the 
exception, and the majority of states have not taken steps to address this 
expanded focus of public health genetics.   
The aim of this dissertation was to conduct the first studies in 
Kentucky to determine the need for public health genetics programs for 
hereditary cancer syndromes.  In order to conduct these assessments, 
data sources first needed to be identified.  At this time, there is no state or 
national database that provides the information needed to identify all 
individuals who might be appropriate for referral for cancer genetic 
services or to determine who has received genetic testing and what the 
outcome of that testing was.  It is also likely that few data sources exist in 
local environments, but these may be increasing due to the use of 
electronic medical records.  As a result, this needs assessment was 
conducted using two pre-existing data sources:  Kentucky Cancer Registry 
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data and Kentucky Medicaid Claims data.  The studies in this dissertation 
were planned and completed in a manner that the data could be readily 
used to show the need for public health genomics programs and could be 
easily reproduced in other states that are also embarking on a needs 
assessment in this emerging specialty area of public health.  The 
concluding chapter of this dissertation will briefly summarize the results of 
the two studies presented in Chapters 2 and 3.  Based on those results, 
conclusions are drawn, and the implications of these studies both in 
Kentucky and in other states are discussed.  Finally, recommendations for 
future action and research are outlined. The two studies contained in this 
dissertation represent the first effort to assess the need for public health 
action in Kentucky to address HBOC and LS.   
B. SUMMARY OF RESULTS 
Paper 1, “An Assessment of Kentucky Cancer Registry Data for 
Appropriate Referral to Genetic Services for Hereditary Breast and 
Ovarian Cancer syndrome and Lynch syndrome, 2009-2012,” utilized 
Kentucky Cancer Registry data to determine the number of individuals 
diagnosed with cancer between 2009 and 2012 who would meet select 
nationally established clinical criteria for referral to genetic counseling 
services.  The study also assessed whether the current genetic 
counselors employed in Kentucky would be able to manage the increase 
in referrals that would likely result from the implementation of programs to 
increase patient identification.  The results of Paper 1 show that there are 
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a significant number of individuals diagnosed with breast, ovarian, 
fallopian tube, endometrial and colorectal cancers each year in Kentucky 
who are appropriate for referral for genetic services for HBOC or LS.  
Between 2009 and 2012, 15,477 breast, ovarian, fallopian tube, 
endometrial and colorectal cancers (55.1% of all diagnosed cases of these 
cancers during the same time period) were determined to be appropriate 
for referral to genetic services.  The cases that were identified as 
appropriate for referral had an overrepresentation of diagnoses at more 
advanced stages (Stage 3 or 4 33.21%) and of diagnoses under the age 
of 50 (31.08%), largely due to young age at diagnosis being an indicator 
for referral.   
An analysis of appropriate cases for referral by county in 2012 
showed that every county had residents who were diagnosed with one of 
the cancers included in this study and were appropriate for referral.  The 
highest number of cases occurred in Jefferson County (n=729, 18.38% of 
cases identified in Kentucky), Fayette County (n=255, 6.43% of cases 
identified in Kentucky) and Kenton County (n=108, 2.72% of cases 
identified in Kentucky).  These three counties also house all of the full-time 
on-site genetic counseling services in Kentucky.  Genetic counselors at 
these institutions provide outreach and/or telemedicine services in 9 
additional counties; however, 90% of Kentucky counties do not have 
genetic counseling services available in the county.  Area development 
districts (ADDs) were also assessed for appropriate cases and genetic 
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counseling services.  The study found that 75% of individuals who were 
identified as appropriate for referral to genetic services in 2012 would 
have been able to access these services in their ADD. Six of the 15 ADDs 
lack locally available genetic counseling services. This data was 
presented as count data in order to illustrate the need for genetic 
counseling services across the state and to provide local leaders with a 
tangible number of people who would utilize these services.   
An assessment of genetic counselors in Kentucky shows that there 
are currently 10.5 genetic counselors providing cancer genetic counseling 
services in the state.  This study estimates that at minimum 10 genetic 
counselors will be needed just to provide services to individuals newly 
diagnosed with cancer in Kentucky each year and their relatives.  
Additional genetic counselors will be needed to provide services to those 
individuals previously diagnosed with cancer who did not receive genetic 
counseling, individuals who have not been diagnosed with cancer but are 
appropriate for referral, individuals at risk for hereditary cancer syndromes 
other than HBOC and LS, and individuals diagnosed with cancer who 
have a family history of cancer suggestive of HBOC or LS.  Should a 
state-wide program be implemented to improve identification of patients 
appropriate for referral to genetic services, Kentucky does not have the 
genetic professional workforce to manage the increase in referrals.   
Paper 2, “Utilizing Medicaid Claims Data to Assess the Use of 
Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome in 
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Kentucky and Characteristics that Influence Genetic Testing Completion,” 
is a secondary data analysis of Kentucky Medicaid Claims data between 
2009 and 2012 for individuals who had a claim with an associated 
diagnosis code for breast cancer (174.*), male breast cancer (175.*), 
ovarian cancer (183.0) or fallopian tube cancer (183.2).  This data analysis 
determined that during the time span of this study, 3144 individuals had a 
claim associated with one of the cancers of interest in this study and met 
the outlined criteria for referral to genetic services.  This included 1849 
women diagnosed with breast cancer under age 50, 74 males diagnosed 
with breast cancer, and 1221 women diagnosed with ovarian or fallopian 
tube cancer.  Of these individuals, 241 (7.7%) had a claim for genetic 
testing.   
Several variables were found to be associated with the outcome 
variable genetic testing (yes/no).  Logistic regression showed that for 
every 5 year increase in patient age (earliest age at the time of claim 
included in the data set), the odds of an individual having genetic testing 
decreased by 13.2% (p<0.0001).  Cancer type also significantly affected 
whether an individual had a claim for genetic testing with women 
diagnosed with breast cancer having 9.137 times the odds of having 
testing than women diagnosed with ovarian or fallopian tube cancer 
(p<0.0001).  No males diagnosed with breast cancer identified in this data 
set had a claim for genetic testing, despite 25% or more of male breast 
cancers being due to HBOC.  Having one or more claims from a 
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gynecologist (p=0.0083) or oncologist (p<0.0001) during the study period 
also increased a person’s odds of having a genetic testing claim.   
This study found that several variables previously discussed in the 
literature as having an effect on referral to and/or uptake of genetic testing 
were not statistically significantly associated with having a genetic testing 
claim.  These included race, distance from a genetic counseling clinic, and 
living in an Appalachian designated county.   
C. CONCLUSIONS 
 When considered together, the two studies included in this 
dissertation provide preliminary information regarding the need for and 
use of genetic testing for hereditary cancer syndromes in Kentucky.  
Paper 1 shows that there are a significant number of individuals 
diagnosed with cancer each year who should be referred for genetic 
counseling and testing services in Kentucky, and Paper 2 provides 
evidence that the utilization of genetic testing services is low.  This 
information should be used to begin discussions with state and local public 
health leaders about the importance of further investigating the role of 
public health genetics in Kentucky.  Genetics providers should also be 
engaged and encouraged to share best practices among clinics and with 
public health leaders.  Genetic providers can also likely provide valuable 
information about the barriers in Kentucky to obtaining patient referrals 
and providing services that can then be taken into account during future 
public health genetics program development.  Given the results of this 
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dissertation, developing policies and programs to increase awareness and 
knowledge of genetic counseling for hereditary cancer syndromes should 
also be strongly considered.  Programs designed to more uniformly 
provide referrals to at-risk individuals should also be considered.  It would 
also be important to involve the genetic counseling community in helping 
to develop strategies for expanding the genetic counseling workforce, as 
these studies suggest that if programs were implemented to increase 
referral to and use of genetic counseling services, it is likely that the 
genetic counseling workforce in Kentucky would need to increase.    
 The results of these studies also begin to show the type of impact 
that an increase in referral to genetic counseling services can have on 
cancer prevention in Kentucky.  Two of the cancers for which individuals 
with HBOC are at increased risk, breast and ovarian cancers, are the 
second and fifth causes of cancer deaths in women.  It is estimated that 
HBOC is responsible for approximately 5% of female breast cancer (9.5% 
of breast cancers diagnosed under age 50) and up to 18% of ovarian 
cancers5,6,8.  It is estimated that LS causes 2-4% of colon cancers12.  If 
individuals with these hereditary cancer syndromes were routinely 
identified before cancer developed, there are screening and prevention 
methods that can significantly reduce the risks for these cancers.  Based 
on the data obtained from the Kentucky Cancer Registry, 192 cases of 
breast cancer (5% of 3846 diagnoses), 54 ovarian and fallopian tube 
cancers (18% of 303) and 50 colon cancers (2% of 2470) could have been 
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prevented in 2012 alone had individuals with HBOC and LS been 
uniformly identified on a consistent basis prior to cancer development or 
diagnosed at earlier stages through increased screening.  Of course, not 
all patients identified through these programs would choose to pursue 
genetic testing, but all individuals should be informed about the availability 
of testing. 
D. IMPLICATIONS 
 The results of this dissertation have implications for public health 
practice in Kentucky and other states.  Although the information contained 
in this dissertation is specific to Kentucky, it is likely that similar situations 
exist in other states that have not previously done significant work with 
genetic conditions that have tier 1 genomic applications.  Each state will 
have unique circumstances and will need to conduct an independent 
needs assessment, but it is likely that the methods used in this 
dissertation can be replicated in other states with similar sources of data. 
 In Kentucky, these results have a number of implications for the 
public health, healthcare, and genetic services workforces.  Currently, 
public health genetics in Kentucky focuses solely on newborn screening 
and short term follow-up of infants with positive screening results.  The 
results of this dissertation have revealed a significant gap in public health 
services in Kentucky that would have a significant impact on cancer 
prevention efforts.  When considering public health genetics and cancer, 
the state of Kentucky currently fulfills none of the 10 Essential Public 
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Health Services, but this research provides preliminary information to 
monitor health status, investigate health problems, and inform, educate 
and empower people about the health issue of hereditary cancer. Unlike 
other screening and prevention programs for cancer, identifying 
individuals at risk for hereditary cancer syndromes allows for targeted 
interventions in individuals with the highest risks of developing cancers.  
While traditional cancer prevention programs remain important, we cannot 
continue to ignore the unique needs of individuals with hereditary cancer.  
While resources would certainly need to be allocated to growing public 
health genetics in Kentucky and educating the existing public health 
workforce about the importance of genetics in the care of patients with 
common disease such as cancer, these efforts have the potential for 
significant benefits.   
Although cancer genetic services have been offered in Kentucky 
since the introduction of BRCA1 and BRCA2 testing, these services have 
often been fragmented.  Kentucky currently does not have a state genetics 
professional organization, regular meetings for genetics professionals, or 
a consistent method for genetic professionals to share ideas and best 
practices.  If we are to move genetic counseling for hereditary cancer 
syndromes from a one provider, one patient model to a public health 
based model, the genetic counseling community in Kentucky will need to 
address these issues.  An expansion of public health genetics in Kentucky 
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will be most successful if a unified effort is made by the genetic counseling 
community to promote the importance of such programs. 
E. RECOMMENDATIONS 
The results from this dissertation provide a significant contribution 
to the literature regarding genetic counseling and testing in Kentucky, 
specifically for the Tier 1 Genomic Applications for HBOC and LS.  Based 
on these results, it is recommended that the state health departments, 
local health departments, genetic providers and healthcare institutions in 
Kentucky begin to consider the growing impact of genetics on cancer 
screening, prevention and treatment.  The first step in this process is 
education.  Public health workers, healthcare providers and the public 
need to be educated about genetics and the importance of genetic risk 
assessment and testing in cancer prevention.  Furthermore, a focus on 
increasing awareness of genetic services in Kentucky is imperative.  
Although genetic counseling services are only provided full-time on site in 
three cities (Louisville, Lexington, and Covington) there are a number of 
outreach clinics and telemedicine clinics available to residents who live 
outside these cities.  However, it would be difficult for providers to refer to 
these services if they are unaware of their availability.  Currently, Kentucky 
does not have a listing of genetic counselors providing services in the 
state or any other state-wide resources regarding genetic testing and 
hereditary cancer syndromes.   
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In order to assure services to those who are at risk for hereditary 
cancer syndromes, new and innovative programs will need to be 
considered as the model for genetic services transitions from a one 
provider, one patient model to population based methods.  One type of 
program that has been implemented in other states and is included in the 
CDC’s Tier 1 Genomic Applications Toolkit is bidirectional cancer registry 
reporting.  Bidirectional cancer registry reporting involves applying 
evidence-based guidelines for the identification of individuals at-risk for 
hereditary cancer syndromes to the submitted case data to identify those 
individuals diagnosed with cancer in the state who should have a referral 
to genetic counseling services.  This information is then reported back to 
the healthcare institutions, physicians, and/or patients directly along with 
information about hereditary cancer and accessing genetic counseling 
services.  Given that state cancer registries receive information on all 
cases of cancer diagnosed in a state, this type of program helps to 
promote uniform referral of appropriate patients.  This would help to 
overcome some of the disparities associated with genetic counseling 
identified in this dissertation.  Specifically, this type of program would help 
to reach individuals who live in Appalachian counties, see physicians who 
are not aware of genetic counseling services or referral criteria, or are not 
diagnosed at a very young age with cancer.  Recently, the CDC and the 
Genetic Alliance have worked to create additional resources for states 
interested in implementing bidirectional cancer registry reporting 
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programs, including an educational video about bidirectional cancer 
registry reporting for providers, written materials that can be used to report 
back cancer registry data to institutions, and educational information for 
providers and patients including a full length slide set on HBOC and LS34.   
 Although this dissertation is the first to assess the need in Kentucky 
for cancer genetic counseling services, additional research needs to be 
done in order to further determine the specific needs of Kentucky 
residents that should be considered as public health genetics and 
genomics programs are planned and implemented.  Additional studies 
should focus on: 
1. Determining provider identified barriers to referring patients for 
genetic counseling for hereditary cancer syndromes. 
2. Exploring methods to document cancer family history and barriers 
to the accurate documentation of this information.  A future study 
on this topic could look at the family history question currently 
included in data reported to the Kentucky Cancer Registry.  Key 
informant interviews could then be carried out with cancer registrars 
and/or providers at healthcare organizations to determine barriers 
to accurately documenting this information.  The development and 
inclusion of additional family history questions on the Kentucky 
Cancer Registry abstracting forms to more accurately document 
family history for identification of appropriate patients for genetic 
services should also be explored. 
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3. Assessment of current programs in Kentucky being conducted by 
genetics professionals, healthcare systems, state public health 
departments, and local public health departments that include 
information on genetics and genomics related to Tier 1 Genomic 
Applications or could have this information easily assimilated into 
the existing program.  By understanding what is currently being 
done in Kentucky, gaps can be identified and addressed in the 
development and implementation of future programs.  Having 
documentation of current efforts in public health genomics will also 
help to prevent duplication of efforts and resources.   
4. Review health insurance plans in Kentucky to determine whether 
these plans have guidelines that follow the national, evidence-
based guidelines for referral to cancer genetic services.   
5. Implementation of a pilot project of bidirectional cancer registry 
reporting.  The Kentucky Cancer Registry is a valuable resource to 
the state of Kentucky and has the potential to play an important role 
in the advancement of public health genetics and genomics in the 
state.   
These studies and others will be needed in order to more fully 
understand how to implement programs that will best address the needs 
of Kentucky residents.  However, conducting these studies and pilot 
projects will require funding and time, both of which are in short supply.  
Currently, there is sparse funding for public health genetics and genomics 
95 
 
outside of newborn screening, although some resources do exist.  
Funding sources include the CDC Office of Public Health Genomics, 
Healthy People 2020 grants, and other grant resources.  The preliminary 
information contributed by this dissertation combined with the results of 
future studies could be utilized to help secure grant funding for Kentucky 
in the future. 
A second barrier to implementing programs in public health genetics in 
the state of Kentucky is the sparse genetic counseling workforce.  Just as 
there is little funding available for public health genetics and genomics, it 
can be difficult to justify the addition of genetic counselors in a healthcare 
system because these departments often do not produce significant 
revenue.  This is partially due to the way that genetic counseling services 
can be billed, which can be especially difficult if the state does not license 
genetic counselors, as is the case in Kentucky.  Recently, there has been 
an effort to pass a licensure bill at the state level to establish licensure for 
genetic counselors, and these efforts are ongoing.  Public health 
practitioners and healthcare systems should support these efforts moving 
forward as this is an important step in expanding the genetic counseling 
workforce and preparing Kentucky for the increasing need for genetic 
services. 
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APPENDIX 1 
Cancer Genetic Counseling Clinics in Kentucky April 2015 
Genetic 
Counseling 
Clinic Main 
Site County ADD 
Cancer Outreach 
Clinics County ADD 
University of 
Louisville 
Jefferson KIPDA 
Brown Cancer Center Jefferson KIPDA 
Baptist Hospital East Jefferson KIPDA 
St. Mary's Hospital (IN) n/a n/a 
St. Joseph Hospital Fayette Bluegrass 
St. Joseph Hospital 
East Fayette Bluegrass 
Mitchell Memorial 
Cancer Center Daviess Green River 
Flaget Memorial 
Hospital Nelson Lincoln Trail 
Kentucky One Jefferson KIPDA None     
Norton 
Healthcare Jefferson KIPDA None     
Baptist Health 
Lexington 
Fayette Bluegrass 
Baptist Health Madison Madison Bluegrass 
Baptist Health Cordin Whitley 
Cumberland 
Valley 
Hardin Memorial Health Hardin Lincoln Trail 
Baptist Health 
Madisonville Hopkins Pennyrile 
University of 
Kentucky 
Fayette Bluegrass 
St. Claire Regional 
Medical Center* Rowan Gateway 
Hazard ARH Medical 
Mall Perry 
Kentucky 
River 
St. Elizabeth 
Healthcare Kenton 
Northern 
Kentucky 
St. Elizabeth Ft. 
Thomas Campbell 
Northern 
Kentucky 
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